Maternal Pregnancy-Associated Circulating MicroRNA predictors of

infant birth outcomes are Determinants of Placental Maturation

[1]Alexander M. Tseng, [1]Amanda H. Mahnke, [2,3]Alan B. Wells, [1]Nihal A. Salem, [4]Andrea M. Allan,

[5]Victoria H.J. Roberts, [6]Natali Newman, [6]Nicole A.R. Walter, [6]Christopher D. Kroenke, [6]Kathleen

A. Grant, [7]Lisa K. Akison, [7]Karen M. Moritz, [2,3†]Christina D. Chambers, [1†]Rajesh C. Miranda &

[#]CIFASD

[1]Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health

Science Center, Bryan, TX, USA

[2]Clinical and Translational Research Institute, University of California San Diego, San Diego, CA,

USA

[3]Department of Pediatrics, University of California San Diego, San Diego, CA, USA

[4]Department of Neurosciences, University of New Mexico, Albuquerque, NM, USA

[5]Division of Reproductive and Developmental Sciences, Oregon National Primate Research

Center, Oregon Health & Science University, Portland, OR, USA

[6]Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science

University, Portland, OR, USA

[7]Child Health Research Centre and School of Biomedical Sciences, the University of Queensland,

4072, Brisbane, Australia

[†] Co-senior authors to whom correspondence should be addressed:

Dr. Rajesh Miranda,

email: miranda@medicine.tamhsc.edu

Texas A&M University Health Science Center, College of Medicine, Department of Neuroscience

& Experimental Therapeutics, Medical Research and Education Building 8447 Riverside

Parkway, Bryan, TX 77807-3260

Phone: 979-436-0332 Fax: 979-436-0086

Dr. Christina Chambers

email: chchambers@ucsd.edu

University of California San Diego, Department of Pediatrics, 9500 Gilman Drive MC 0828, La

Jolla, CA 92093

Phone: 858-246-1704, Fax: 858246-1701

#CIFASD, Collaborative Initiative on Fetal Alcohol Spectrum Disorders

Acknowledgements:

This research was supported by grants from the NIH, P50 AA022534 (AMA), U01 AA014835 and

the Office of Dietary Supplements (CDC), R24 AA019431 (KAG), R01 AA021981 (CDK), R01

AA024659 (RCM), F31 AA026505 (AMT) and support from National Health and Medical

Research Council of Australia (KMM). We thank CIFASD for intellectual support and Megan S.

Pope and Tenley E. Lehman for their assistance in conducting cell culture and animal studies.

Data on human subjects is deposited at CIFASD.org, in accordance with NIH data repository

guidelines.

Conflict of Interest Statement

The authors have declared that no conflict of interest exists.

Abstract

We previously identified 11 miRNAs which were significantly elevated in blood plasma of pregnant mothers who subsequently gave birth to infants affected by prenatal alcohol exposure (PAE, Heavily Exposed Affected: HEa) compared to those with infants who were exposed but apparently unaffected (Heavily Exposed Unaffected: HEua) or unexposed (UE). These maternal $_{HEa}$miRNAs were predicted to originate in part, as a paracrine placental signal to influence and coordinate placental epithelial-mesenchymal transition (EMT), a pathway essential for endometrial invasion and development. We now report that PAE inhibits expression of placental EMT pathway members in rodent and primate voluntary alcohol consumption models, with $_{HEa}$miRNAs collectively mediating placental EMT inhibition. To directly investigate the interaction between $_{HEa}$miRNAs and ethanol on placenta, we assessed their effects on human placental trophoblast cell lines. When administered together, $_{HEa}$miRNAs retarded trophoblast cell cycle, significantly impaired expression of core EMT pathway members, and reduced invasiveness, pointing to their collective role in modulating placental growth and invasion deficits seen with PAE. $_{HEa}$miRNAs additionally interfered with maturation-dependent intracellular calcium dynamics, while promoting syncytialization-dependent increases in placental hormone expression. Finally, a single systemic administration of the pooled murine-expressed $_{HEa}$miRNA subpopulation, to pregnant mice, decreased fetal and placental growth and inhibited expression of EMT pathway mRNA transcripts in placenta. Taken together, our data suggests that, following PAE, $_{HEa}$miRNAs interfere with placental development and may contribute to the pathology of Fetal Alcohol Spectrum Disorders.

Introduction

Alcohol use during pregnancy remains prevalent despite published prevention guidelines (1). A recent meta-analysis determined the global prevalence of alcohol use during pregnancy at 9.8% (2). Within the United States, a 2013 study found 18% of women reported alcohol consumption during pregnancy, and 6.6% engaged in binge-drinking episodes, which are particularly damaging to fetal development (3). In the state of Texas, we recently reported an average state-wide third-trimester rate of alcohol exposure of 8.4%, with rates as high as 17.7% in some localities (4). These data collectively suggest that prenatal alcohol exposure (PAE) is common.

PAE harms the developing embryo and fetus and can result in a constellation of adverse infant outcomes, including craniofacial dysmorphologies, growth retardation, and neurobehavioral abnormalities, collectively termed Fetal Alcohol Spectrum Disorders (FASDs) (5). Estimates for the prevalence of FASDs range from 2-5% of the school age population in the US and Western Europe (6) to 13.6-20.9% in South Africa (7). Estimates for the global prevalence of fetal alcohol syndrome (FAS), the most severe end of the FASD continuum, characterized by cranio-facial dysmorphologies, growth restriction, and CNS abnormalities, range from 0.15 to 0.3% (8, 9), but are much higher in specific populations, for example, as high as 5.9-9.1% in the Cape Coloured (mixed ancestry) community in South Africa (7).

Given the lifelong debility and economic burden associated with FASDs (10), there is an urgent need to develop sensitive and specific methodologies to identify affected children early in development, as well as develop interventions which can mitigate the effects of PAE on the developing fetus. In 2016, we reported that elevated levels of 11 distinct microRNAs (miRNAs)

in 2nd and 3rd trimester maternal circulation distinguished infants who were affected by in-utero

alcohol exposure (Heavily Exposed Affected: HEa) from those who were apparently unaffected

at birth by PAE (Heavily Exposed Unaffected: HEua), or those who were unexposed (UE) (11) .

We predicted that these $_{HEa}$miRNAs (MIMAT0004569 [hsa-miR-222-5p], MIMAT0004561 [hsa-

miR-187-5p], MIMAT0000687 [hsa-mir-299-3p], MIMAT0004765 [hsa-miR-491-3p],

MIMAT0004948 [hsa-miR-885-3p], MIMAT0002842 [hsa-miR-518f-3p], MIMAT0004957 [hsa-

miR-760], MIMAT0003880 [hsa-miR-671-5p], MIMAT0001541 [hsa-miR-449a], MIMAT0000265

[hsa-miR-204-5p], MIMAT0002869 [has-miR-519a-3p]) in addition to being biomarkers of infant

outcome following PAE, influence signaling pathways crucial for early development, particularly

the epithelial-mesenchymal transition (EMT) pathway (11).

Placental development involves maturation of the cytotrophoblasts at the tip of

anchoring villi into invasive extravillous trophoblasts, as well as fusion of cytotrophoblasts into

multinucleate, hormone-producing syncytiotrophoblasts (12). Maturation into extravillous

trophoblasts, which invade the maternal decidua and remodel the uterine spiral arteries into

low-resistance high-flow vessels that enable optimal perfusion for nutrient and waste

exchange, requires cytotrophoblasts to undergo EMT (13). Impaired placental EMT, as well as

orchestration of the opposing mesenchymal-epithelial transition pathway, has been found in

conditions resulting from placental malfunction, primarily preeclampsia (14-19). While there

have been no previous studies directly investigating the effects of PAE on placental EMT, a

rodent study demonstrated that PAE, during a broad developmental window, reduced the

number of invasive trophoblasts within the mesometrial triangle, a region of the uterine horn

directly underlying the decidua (20). Furthermore, both human and rodent studies have found

PAE disrupts placental morphology, and interferes with cytotrophoblast maturation, as with

preeclampsia (21-24). Disrupted trophoblast maturation, seen in these conditions, is associated

with aberrant expression of placental hormones, primarily human chorionic gonadotropin

(hCG) (25-28). Our study is the first to report that PAE interferes with expression of core

placental EMT pathway members. We also provide evidence that a group of circulating

maternal miRNAs, HEamiRNAs, which predict adverse infant outcomes due to PAE, mediate

some of PAE's effects and interfere with EMT and cytotrophoblast maturation.

Results

<u>HEamiRNAs are implicated in placental-associated pathologies</u>

Outside of our report that elevated HEamiRNA levels predict infant outcomes following

PAE, few other studies have investigated expression of these miRNAs in the context of PAE or

other potentially toxic prenatal exposures (Figure 1A) (29-36). Given our prediction that

HEamiRNAs interfere with signaling pathways governing fetal and placental development (11),

we conducted a literature review of reports on HEamiRNA levels in gestational pathologies

which, as with PAE, include aberrant placentation as an etiological factor (37-39). Surprisingly,

placental and plasma levels of 8 out of 11 of these HEamiRNAs were significantly dysregulated in

one or more of these gestational pathologies with expression of the majority of these 8 miRNAs

altered in both fetal growth restriction and preeclampsia (Figure 1B) (33, 34, 36, 40-57), both of

which are characterized by poor placental invasion as an etiological factor (58-64).

<u>HEamiRNAs explain variance in infant growth outcomes due to PAE</u>

Given the association of individual HEamiRNAs with gestational pathologies, we sought to

determine if circulating HEamiRNAs levels could explain the variance in sex and gestational age-

adjusted neonatal height, weight and head circumference in our Ukrainian birth cohort, which

are growth measures sensitive to in utero environment (65). We found that 8 of the HEamiRNAs,

each significantly explained between 7 to 19% of infant variation in these growth measures

(Table 1). Furthermore, 7 of these miRNAs were also associated with fetal growth restriction

and preeclampsia as identified by our literature review. Additionally, only 1 of the 3 miRNAs not

previously-reported to be associated with gestational pathologies was correlated with

measures of fetal growth and development in our dataset (Figure 1B). Interestingly, a

multivariate statistical regression model that accounted for levels of all 11 HEamiRNAs together,

explained a far greater proportion of infant variance, between 24-31%, in all three growth

measures than accounting for them individually (Supplementary Table 2).

<u>HEamiRNAs are transcribed preferentially in the placenta</u>

Data extracted from publicly available gene expression profiling datasets (66) show that

HEamiRNAs as well as their unprocessed precursor transcripts, HEapri-miRNAs, are enriched in

placenta compared to other tissues, suggesting that the placenta itself transcribes these

miRNAs and may be a significant contributory tissue to maternal circulating HEamiRNAs (Figures

1C and D). Since chorionic villi are immersed in maternal blood, it is possible that the placenta is

both a source and a target of maternal HEamiRNAs. Moreover, since HEamiRNAs are also

associated with gestational pathologies caused by poor placental invasion, these HEamiRNAs

may also constitute an intra-placental paracrine signal to coordinate the (mal)adaptive

response of tissues to PAE. We therefore assessed in rodent and primate models, whether PAE

could result in impaired EMT, and if HEamiRNAs could explain the effects of PAE on placental

EMT-associated gene expression.

<u>HEamiRNAs moderate PAE's effects on EMT pathway members</u>

EMT, in trophoblasts, is characterized by the disappearance of epithelial markers like E-

Cadherin and the appearance of the mesenchymal markers like the intermediate filament,

vimentin, a process that is controlled by the expression of key mesenchymal determination

transcription factors, Snail1 and 2 and TWIST, as extensively described (13, 17, 18, 67-70).

These five markers have been used extensively to assess EMT in a variety of model systems, so

our studies utilized these markers to assess the effects of alcohol and $_{HEa}$miRNAs on trophoblast

EMT.

In the first analysis, using a murine model of PAE that mimicked moderate to binge-type

alcohol consumption throughout early and mid-pregnancy, we fractionated GD14 placenta into

three zones: the cytotrophoblast and syncytiotrophoblast rich labyrinth zone, the glycogen and

spongiotrophoblast rich junctional zone, and the decidual zone comprising the endometrial

contribution to the placenta (Figure 2A). Multivariate analysis of variance (MANOVA) for

expression of these five core genes in the EMT pathway within placental trophoblasts, revealed

a significant effect of ethanol exposure on EMT pathway member expression selectively within

the labyrinth zone (Pillai's trace statistic, $F_{(5,21)}=6.85$, $p<0.001$, Figure 2B) but not within the

junctional or decidual zones. Post-hoc univariate ANOVA indicated ethanol exposure specifically

elevated *CDH1* ($F_{(1,25)}=7.452$, $p=0.011$), which encodes epithelial E-Cadherin, whereas

expression of the pro-mesenchymal transcription factor *SNAI1* was significantly reduced

($F_{(1,25)}=21.022$, $p=0.0001$). We also observed a significant interaction between fetal sex and PAE

on expression of *SNAI2* ($F_{(1,25)}=2.18$, $p=0.047$) and a trend towards decreased expression of the

terminal mesenchymal marker *VIM* (Vimentin, $F_{(1,25)}=2.749$, $p=0.11$), while there was no effect

on *TWIST* expression (Figures 3A-3E). Consistent with our gene expression data, E-Cadherin

protein levels were significantly elevated in the labyrinth zone of PAE placenta ($F_{(1,24)}=31.63$,

$p=0.0005$), while not in the junctional or decidual zones (Figure 3F and Supplementary Figures

3A and B). However, when we controlled for expression of the 8 mouse homologues of

$_{HEa}$miRNAs as a covariate, using multivariate analysis of covariance (MANCOVA), ethanol's effect

on EMT became marginally nonsignificant (Pillai's trace, $F_{(5,21)}$=2.713, p=0.068) (Figure 2C),

suggesting that these miRNAs partially mediate effects of PAE on EMT pathway members in

mice. Interestingly, PAE limited to the peri-conceptional period in rats also influenced

expression of EMT core transcripts (Supplementary Figures 2B and 4A-4E).

To determine if PAE's effects on EMT pathway members in placenta are broadly

conserved throughout mammalian evolution, we adopted a non-human primate (macaque)

model of moderate to binge-type alcohol consumption. Placental tissues were isolated from

GD85, GD110, and GD 135 placenta (Figure 2D), which spans the human equivalent of mid-

second to mid-third trimester (Supplementary Figure 2C). There was a significant effect of

ethanol exposure on expression of core EMT mRNA transcripts by MANOVA (Pillai's trace

statistic, $F_{(4,9)}$=4.229 p=0.045, Figure 3B). Consistent with our findings in mouse, post-hoc

univariate ANOVA indicated that in primate placenta, ethanol exposure significantly increased

CDH1 expression ($F_{(1,12)}$=4.866, p=0.048) whereas *VIM* expression was significantly reduced

($F_{(1,12)}$=12.782, p=0.0004), suggesting that, as in the mouse, PAE also impairs EMT in the primate

placenta. Interestingly, there was no effect on *SNAI2* or *TWIST* expression (Figures 3G-3J). As in

mice, accounting for expression of HEamiRNAs together as a covariate abolished the significant

effect of PAE on EMT, though to a greater degree than mice (Pillai's trace, $F_{(1,1)}$=1.605, p=0.425,

Figure 2E). Interestingly, accounting for expression of individual HEamiRNAs did not explain the

effects of PAE on placental EMT, suggesting that HEamiRNAs act in concert to mediate the effect

of PAE on EMT in primate placenta (Figure 2F).

Collectively, our data suggests PAE induced impairment of EMT in the trophoblastic

compartment of placentae is conserved between rodents and non-human primates and that

HEamiRNAs, particularly in primates, may moderate the effect of PAE on placental EMT.

Consequently, subsequent studies focused on the collective role of HEamiRNAs, either on basal

or on alcohol-influenced placental trophoblast growth, invasion, and the maturation of

physiological function.

HEamiRNAs impair EMT pathway member expression in a model of human cytotrophoblasts

To investigate whether HEamiRNAs collectively interfere with the EMT pathway, as

suggested by our in vivo data, we measured expression of core members of the EMT pathway

after transfecting HEamiRNA mimics and antagomirs into BeWO cytotrophoblasts.

Cytotrophoblasts normally undergo EMT to become invasive trophoblasts, which we also

modelled using the HTR8 human extravillous trophoblast cell line. We initially overexpressed

each of the 11 HEamiRNAs individually, to determine whether any of them could alter mRNA

transcripts for EMT pathway members. However, we did not observe any significant effects due

to overexpression of individual miRNAs (Supplementary Figure 5), consistent with our findings

in the primate PAE model that individual miRNAs did not explain the effects of ethanol on EMT.

In contrast, transfection of pooled HEamiRNAs into cytotrophoblasts significantly increased *CDH1*

expression ($F_{(1,36)}$=30.08, p<0.0001). Interestingly, expression of the pro-mesenchymal

transcription factors *TWIST* and *SNAI1* were also significantly reduced, but only in the context of

concomitant 320 mg/dL ethanol treatment, pointing to an interaction effect between

HEamiRNAs and ethanol ($F_{(1,36)}$= 5.650 and 5.146 respectively, p=0.023 and p=0.029, Figures 4A-

D). Consistent with our qPCR data, transfection of HEamiRNAs also significantly increased E-

cadherin protein expression ($F_{(1,20)}$=33.86, p<0.0001, Figure 4E). We were unable to detect

SNAI2 transcript expression or vimentin protein expression in these cells, consistent with

previous reports (71).

Whereas transfection of HEamiRNA mimics increased *CDH1* expression, transfection of

pooled antagomirs to HEamiRNAs, significantly reduced CDH1 expression, only in the context of

320 mg/dL ethanol co-exposure (post-hoc Tukey's HSD, p=0.005), consistent with an overall

statistically significant interaction effect between ethanol exposure and HEamiRNA inhibition

($F_{(1,36)}$=13.51, p=0.0008, Figure 4F). However, expression of *TWIST* was also decreased in this

context and there was no significant difference in E-Cadherin protein expression relative to the

control (Figure 4G-J). Thus, our data suggest that, increasing HEamiRNA levels impairs EMT

pathway members in cytotrophoblasts whereas inhibiting their action has a more restricted

effect on EMT pathway members.

HEamiRNAs impair EMT member expression in a model of human extravillous trophoblasts

We next investigated the effect of HEamiRNAs on EMT in HTR-8/SVneo extravillous

trophoblast-type cells. Transfecting pooled HEamiRNA mimics into extravillous trophoblasts

significantly decreased *VIM* expression ($F_{(1,36)}$=28.43, p<0.0001). Expression of pro-

mesenchymal transcription factors *SNAI2* was also reduced ($F_{(1,36)}$= 64.88 respectively,

p<0.0001). As with cytotrophoblasts, expression of SNAI1 and *TWIST* were reduced only with

320 mg/dL ethanol co-exposure (post-hoc Tukey's HSD, p =0.027 and p<0.0001 respectively)

indicating an interaction effect ($F_{(1,36)}$=4.21 and 5.18, p=0.048 and 0.029 respectively, Figures

5A-D). Consistent with our qPCR data, Vimentin protein expression was also significantly

reduced ($F_{(1,20)}$=9.535, p=0.006, Figure 5E). Interestingly, there was also a main effect of alcohol

exposure on decreasing vimentin protein expression ($F_{(1,20)}$=7.303, p=0.014). We were unable to

detect expression of *CDH1* transcript, or its E-Cadherin protein product, in extravillous

trophoblasts, consistent with previous reports (71).

In contrast to HEamiRNA mimics, transfecting pooled antagomirs significantly increased

VIM expression ($F_{(1,35)}$=42.56, p<0.0001). Likewise, there were interaction effects for *SNAI1* and

SNAI2 ($F_{(1,35)}$=10.31 and 4.86, p=0.01 and p=0.034 respectively), whereby antagomir

transfection increased expression of Snai2 in the context of 320mg/dL ethanol co-exposure

(post-hoc Tukey's HSD, p<0.0001) and Snai1 under basal conditions (post-hoc Tukey's HSD,

p<0.0001)(Figures 5F-I). Despite our qPCR data, we did not observe significant differences in

vimentin protein expression between treatment groups (Figure 5J). Collectively, our data

indicate that increased trophoblastic HEamiRNA levels favors an epithelial phenotype, whereas

inhibiting their action promotes a mesenchymal phenotype.

<u>Antagomirs prevent HEamiRNAs' inhibition of EMT pathway members</u>

We next investigated if pretreating trophoblasts with pooled HEamiRNA antagomirs could

prevent inhibition of the EMT pathway caused by transfecting HEamiRNA mimics. *CDH1*

expression in cytotrophoblasts transfected with control antagomir, and subsequently

transfected with control mimic, was not significantly different from those transfected with

HEamiRNA antagomirs and HEamiRNA mimics. However, *CDH1* was significantly elevated in

cytotrophoblasts transfected with control antagomir and HEamiRNA mimics (post-hoc Tukey's

HSD, n=10 samples per group, p=0.004). Likewise, cells pre-transfected with HEamiRNA

antagomirs had significantly higher *SNAI1* and *VIM* expression than those pre-transfected with

control antagomir and subsequently transfected with $_{HEa}$miRNA mimics (post-hoc Tukey's HSD,

n=10 samples per group, p=0.007 and p<0.0001 respectively) (Figure 6A-D).

Furthermore, *VIM* expression in extravillous trophoblasts pre-transfected with control

antagomir, and subsequently transfected with control mimic, was not significantly different

from those transfected with $_{HEa}$miRNA antagomirs and $_{HEa}$miRNA mimics. However, *VIM*, *SNAI1*,

and *SNAI2* expression were significantly reduced in cytotrophoblasts transfected with control

antagomir and $_{HEa}$miRNA mimics (post-hoc Tukey's HSD, n=10 samples per group, p<0.0001,

Figure 6E-H). Thus, our data suggest that pretreating cells with $_{HEa}$miRNA antagomirs prevents

inhibition of EMT pathway members resulting from transfection with $_{HEa}$miRNA mimics in

cytotrophoblasts and extravillous trophoblasts.

$_{HEa}$miRNAs impair extravillous trophoblast invasion

Functionally, inhibition of the EMT pathway should reduce trophoblast invasiveness.

Thus, we performed a transwell invasion assay using HTR8 extravillous trophoblasts transfected

with $_{HEa}$miRNA mimics and antagomirs. While ethanol exposure by itself did not impair

trophoblast invasion (Supplementary Figure 6), there was a marginally significant interaction

effect between ethanol exposure and $_{HEa}$miRNA mimic transfection (F1,28=3.418, p=0.075).

Thus, a planned comparison indicated that transfection with $_{HEa}$miRNA mimics significantly

reduced trophoblast invasion in the context of 320 mg/dL ethanol co-exposure, relative to the

control mimics (t(14)=2.762, p=0.015), consistent with our data demonstrating $_{HEa}$miRNAs

interfere with the EMT pathway (Figure 7A). Contrastingly, transfecting $_{HEa}$miRNA antagomirs

increased invasion in the context of 320 mg/dL ethanol co-exposure, though this effect was

only marginally significant (t(14)=1.805, p=0.093, Figure 7B).

<u>HEamiRNAs retard trophoblast cell cycle progression</u>

Given the proliferative nature of cytotrophoblasts, and the intimate relationship

between EMT and cell cycle (72, 73), we assessed the effects of ethanol and HEamiRNAs on

BeWO cytotrophoblast cell cycle. After pulse-labeling cells with the nucleic acid analog, EdU, for

1-hour, we found that individually transfecting 6 of the HEamiRNA mimics increased EdU

incorporation (Unpaired t-test, p<0.05, FDR correction), suggesting an overall increased rate of

DNA synthesis (Supplementary Figure 7A). Contrastingly, simultaneous transfection of

HEamiRNAs significantly reduced EdU incorporation($F_{(1,26)}$=59.69, p<0.0001), mirroring the

effects of increasing concentrations of ethanol (R^2=0.304, p=0.012) (Supplementary Figure 7B

and Figure 8A).

Consistent with the increased rates of DNA synthesis resulting from individual HEamiRNA

mimic transfection, individual transfection of HEamiRNAs antagomirs generally reduced EdU

incorporation, though only the antagomir to hsa-miR-760 did so significantly (t(110)=3.059,

p=0.003, FDR correction) (Supplementary Figure 7A). Interestingly, simultaneous administration

of antagomirs also reduced EdU incorporation, as observed with the pooled HEamiRNAs mimics

($F_{(1,26)}$=34.83, p=0.0005, Figure 8B).

To further characterize the coordinated effect of HEamiRNAs on cytotrophoblast cell

cycle, we pulse-labeled cells with EdU for 1-hour and, post-fixation, labelled them with 7AAD to

segregate cells into three groups: G_0/G_1 (7AADlow, EDU-), S (EDU+), and G_2/M (7AADhigh, EDU-

). Both 120 mg/dL and 320 mg/dL ethanol exposures significantly decreased the proportion of

cells in S-phase, while 320 mg/dL exposure increased the proportion of cells in G_2/M-phase,

consistent with the observed reduction in the rate of DNA synthesis (Supplementary Figure 7C).

Similar, to the effects of ethanol exposure, pooled $_{HEa}$miRNA mimic administration also

significantly decreased the proportion of cells in S-phase ($F_{(1,28)}$=52.78, p<0.0001) while

increasing the proportion of cells the G_2/M-phase ($F_{(1,28)}$=8.395, p=0.007) and exacerbated

alcohol's effects on the cell cycle (Figure 8C). Interestingly, pooled $_{HEa}$miRNA antagomir

administration also reduced the proportion of cells in S-phase ($F_{(1,26)}$=14.98, p=0.0007) and

increased the proportion of those in G_2/M-phase ($F_{(1,26)}$=12.38, p=0.002) (Figure 8D).

We sought to determine if pretreating cytotrophoblasts with pooled $_{HEa}$miRNA

antagomirs could prevent the cytotrophoblast cell cycle retardation caused by transfecting

$_{HEa}$miRNA mimics. Cells transfected with the control or pooled $_{HEa}$miRNA antagomirs, and

subsequently transfected with pooled $_{HEa}$miRNA mimics, did not have significantly different cell

cycle profiles or rates of DNA synthesis to each other but had significantly lower rates of DNA

synthesis (ANOVA, $F_{(2,12)}$=16.56, p=0.0004), and a decreased proportion of S-phase cells

($F_{(2,12)}$=11.43, p=0.002) with an increased proportion of cells in G_2/M phase ($F_{(2,12)}$=11.47,

p=0.002), compared to cells transfected with both the control antagomir and control mimic

(Figures 9A and B). Collectively, our data indicate that transfection of these antagomirs

prevents further reduction in the rate of DNA synthesis, or cell cycle retardation, that would

result from transfection with pooled $_{HEa}$miRNA mimics.

$_{HEa}$miRNAs have minimal effect on cell survival

We next sought to investigate whether ethanol- and HEamiRNA-induced changes in cell

cycle were related to an increase in cell death. Only the 320 mg/dL dose of ethanol exposure

demonstrated a slight, but marginally significant effect, of increasing lytic cell death

$(t(18)=2.022, p=0.054)$, though there was no effect on apoptosis (Supplementary Figures 8A and

B). However, the changes in cell cycle following transfection of individual or pooled HEamiRNA

mimics were not mirrored by changes in lytic cell death. Nevertheless, two HEamiRNAs, hsa-mir-

671-5p and hsa-mir-449a, did significantly increase apoptosis (Unpaired t-test, $p<0.05$, FDR

correction) (Supplementary Figures 8C and D).

Contrastingly, transfection of 4 HEamiRNA antagomirs individually, significantly increased

lytic cell death (Unpaired t-test, all $p<0.05$, FDR correction), with the antagomir to hsa-mir-491-

3p also increasing apoptotic cell death $(t(14)=3.383, p=0.004$, FDR correction, Supplementary

Figure 8C and D). Likewise, transfection of pooled HEamiRNA antagomirs increased lytic cell

death $(F_{(1,36)}=11.40, p=0.002)$ but did not cause increased apoptosis (Supplementary Figure 8E-

H). Taken together, our data suggest that while ethanol exposure may increase cytotrophoblast

death, increased levels of HEamiRNAs have minimal effects on cell death, suggesting that their

effect on cell cycle and the EMT pathway is independent of any effect on cell survival.

<u>HEamiRNAs modulate cytotrophoblast differentiation-associated Ca^{2+} dynamics</u>

HEamiRNAs' effects on EMT pathway member expression, coupled with cell cycle

retardation, indicates that HEamiRNAs influence trophoblast maturation. Maturation of

cytotrophoblasts into syncytiotrophoblasts is marked by dramatic changes in the cellular

energetics profile (74). To model HEamiRNAs' effect on hormone-producing

syncytiotrophoblasts, we used a well-established protocol of forskolin induced syncytialization

of BeWO cytotrophoblasts (75, 76). As expected, forskolin treatment induced

fusion/syncytialization of cytotrophoblasts resulting in a greater average cell size in the

forskolin + $_{HEa}$miRNA mimics group ($F_{(1,386)}$=4.386, p=0.037). This suggests that the inhibition of

EMT by these miRNAs may result in preferential syncytialization instead of differentiation to

extravillous trophoblasts (Supplementary Figure 9A). Ethanol and forskolin treatment both

increased baseline calcium levels, as indicated by the change in fluo-4 fluorescence

($F_{(1,426)}$=5.593 and 3.665 respectively, p<0.0001, Figure 10A, Supplementary Figures 9B-D). The

effect of ethanol on baseline calcium was abrogated by $_{HEa}$miRNAs while $_{HEa}$miRNAs + forskolin

was not significantly different to forskolin alone, indicating that forskolin and $_{HEa}$miRNAs may be

affecting similar calcium pathways. Syncytiotrophoblasts actively transport high amounts of

calcium from maternal to fetal circulation, therefore forskolin-exposed trophoblasts likely have

higher basal transport of calcium into the cells due to increased expression of plasma

membrane channels (77). The conversion of trophoblasts to synciotrophoblasts is accompanied

by an increase in endoplasmic reticulum, which could increase calcium buffering capabilities in

response to ethanol-stress on the cells, thus $_{HEa}$miRNA-induced syncytialization pathways may

be protective against ethanol stress.

Adaptations to cellular stress can be seen in alterations to cellular energetics in

response to ethanol, as ethanol-exposed BeWO cells showed decreased baseline and stressed

oxygen consumption rates (OCR) ($F_{(1,28)}$=15.55 and 16.91, p=0.0005 and 0.0003 respectively)

and increased extracellular acidification rates (ECAR) ($F_{(1,28)}$=4.868, p=0.036). However,

$_{HEa}$miRNAs had minimal effects on metabolic activity (Figures 10D-10G).

Extracellular ATP has been shown to inhibit trophoblast migration (78) and can directly

stimulate increased intracellular calcium elevations through purinergic receptors ubiquitously

present on trophoblasts (79). Both $_{HEa}$miRNA and ethanol administration significantly increased

intracellular calcium in response to acute ATP administration ($F_{(1,426)}$=10.34 and $F_{(1,386)}$=16.30,

p=0.001 and p<0.0001 respectively) (Figure 10B). This may be indicative of a lack of

downregulation of purinergic receptors required in trophoblast migration as part of the

interrupted EMT pathway. Forskolin-induced maturation decreased calcium response to ATP

($F_{(1,386)}$=50.72, p<0.0001) (Figure 10C) and prevented the $_{HEa}$miRNA-induced increase in ATP

response. These data agree with previous studies showing increased nuclear trafficking of

ionotropic receptor P2X7 and more localized P2X4 expression over placental development,

which may decrease the overall calcium influx in response to ATP (80).

$_{HEa}$miRNAs promotes syncytialization-dependent hormone production

Transfection of $_{HEa}$miRNA mimics did not change *CGA*, *CGB*, or *IGF2* transcript expression

relative to the control in non-syncytialized trophoblasts. However, following syncytialization,

$_{HEa}$miRNA mimics significantly increased expression of *CGA* and *CGB* (post-hoc Tukey's HSD,

n=10 samples per group, p=0.001 and 0.005 respectively). Consistent with our previous results,

$_{HEa}$miRNA mimics also increased *CDH1* expression in both cytotrophoblasts and

syncytiotrophoblasts ($F_{(1,20)}$=5.286, p=0.032); there was also a main effect of syncytialization on

CDH1 expression, as has been previously reported ($F_{(1,36)}$=3.391, p=0.034, Figures 11A-D).

Likewise, $_{HEa}$miRNAs increased E-cadherin protein expression ($F_{(1,20)}$=5.286, p=0.032), whereas

forskolin decreased it ($F_{(1,20)}$=10.24, p=0.005) (Figure 11E). On the other hand, there was no

effect of $_{HEa}$miRNA antagomirs on *CGA* and *CGB* expression, although we did observe a decrease

in *IGF2* transcript expression, following syncytialization, relative to controls (post-hoc Tukey's

HSD, n=10 samples per group, p=0.001) (Figure 11F-I).

Given that $_{HEa}$miRNAs promotes syncytialization-dependent hormone production, we

next investigated maternal plasma levels of intact human chorionic gonadotropin (hCG) in our

Ukraine birth cohort. Plasma hCG levels were non-significantly increased in the second

trimester of HEa group mothers relative to their UE counterparts, consistent with previous

studies (81). During the third trimester, however, hCG levels remained significantly elevated in

HEa group mothers compared to the UE group (Median Test, n=23 samples in HEa group and

n=22 for HEua and HEa groups, p=0.03) (Figure 12). Furthermore, there was no significant

difference of gestational age at blood draw between the different groups indicating the

increased level of hCG in the HEa group was not confounded by gestational age at which blood

was sampled (Supplementary Figure 10) (82). Interestingly, both alcohol and hCG levels were

negatively associated with gestational age at delivery (GAD), with a significant interaction

between periconceptional alcohol exposure and hCG levels on GAD (Supplementary Table 3).

Taken together, our data suggests $_{HEa}$miRNAs may contribute to PAE-dependent increases in

hCG levels during pregnancy.

<u>$_{HEa}$miRNAs reduce fetal growth</u>

To investigate the functional consequences of elevated circulating $_{HEa}$miRNA levels, we

administered miRNA mimics for the 8-mouse homologue $_{HEa}$miRNAs, or a negative control

mimic, through tail-vein injection to pregnant mouse dams on GD10. On GD18, growth

parameters of male and female fetuses were assessed separately, and data from all same-sex

fetuses from a single pregnancy were averaged into one data point. Dams administered

HEamiRNA mimics produced smaller fetuses than those administered control mimics, according

to all collected measures of fetal size: fetal weight ($F_{(1,17)}$=9.92, p=0.006), crown-rump length

($F_{(1,17)}$=9.89, p=0.006), snout-occipital distance ($F_{(1,17)}$=9.09, p=0.008), and biparietal diameter

($F_{(1,17)}$=5.99, p=0.026) (Figure 13B-E). Interestingly, placental weights were also significantly

reduced in mice treated with HEamiRNA mimics ($F_{(1,17)}$=6.92, p=0.018) (Figure 13F).

Following tail-vein administration of two human-specific sentinel miRNAs, miR-518f-3p

and miR-519a-3p, we found a high biodistribution of both miRNAs in the placenta, comparable

to levels seen in the liver and spleen (Supplementary Figure 11A and 10B). Thus, to determine

whether HEamiRNA's effects on fetal growth could result from their actions on the placenta, we

quantified the placental expression of core EMT members in the GD18 placentas of control and

HEamiRNA fetuses. HEamiRNA administration significantly reduced expression of mesenchymal-

associated transcript *VIM* ($F_{(1,14)}$=14.23, p=0.002) and S*NAI2* ($F_{(1,14)}$=5.99, p=0.028) with a

significant sex by HEamiRNA interaction effect on *SNAI1* ($F_{(1,66)}$=5.55, p=0.034) and *CDH1*

($F_{(1,14)}$=6.01, p=0.028) (Figures 14A-E). Interestingly, and in line with our in vitro findings

whereby HEamiRNAs promoted syncytialization dependent cell fusion and hCG production,

HEamiRNA administration significantly increased expression of the mRNA transcript for *SynB*, a

gene that is important for syncytiotrophoblast maturation ($F_{(1,66)}$=4.11, p=0.047) (Figure 14F).

Discussion

In a prior study, we reported that gestational elevation of 11 maternal plasma miRNAs,

in a Ukrainian clinical cohort, predicted which PAE infants would exhibit adverse outcomes at

birth (11). These $_{HEa}$miRNAs were elevated throughout mid and late-pregnancy, encompassing

critical periods for fetal development, and were predicted to target key developmental

pathways (11). Given that $_{HEa}$miRNAs are placentally enriched and their dysregulation is

associated with placental-associated gestational pathologies, we sought to determine if they

also contributed to the pathophysiology of FASDs.

To mimic the alcohol consumption patterns in our Ukrainian cohort, we adopted

moderate alcohol self-administration paradigms during mouse and macaque gestation. Though

these species share a hemochorial placenta, fundamental differences in placental anatomy

remain. Specifically, macaque trophoblasts exhibit deeper invasion into the uterine horn than

their mouse counterparts (83-86). Despite these differences, we found PAE inhibited

mesenchymal transition-associated mRNA transcripts in both our models, indicating a

conserved effect of PAE on placental development. Additionally, we found that $_{HEa}$miRNAs

mediated the effects of PAE on core EMT pathway members in the placenta, and collectively

though not individually, inhibited EMT in human cytotrophoblast and extravillous trophoblast

culture models. The components of the EMT pathway were selected for assessment based on a

substantial literature that implicates these as core EMT components (13, 17, 18, 67-70).

However, analysis of their 3'UTRs indicates that these are unlikely to be the direct targets of

$_{HEa}$miRNA action. Additional studies will be needed to dissect out the signaling networks that

connect $_{HEa}$miRNAs to the assessed EMT components.

Interestingly, $_{HEa}$miRNAs also promoted syncytialization (forskolin)-dependent hCG

expression, mirroring the elevation of third trimester maternal hCG levels in the PAE group

within our Ukrainian birth cohort. This late-gestation elevation of hCG levels may serve as a

compensatory mechanism to prevent the preterm birth associated with PAE, as hCG during late

gestation is hypothesized to promote uterine myometrial quiescence (87, 88). In support of this

hypothesis, we found significant negative associations between both hCG levels and alcohol

consumption with gestational age at delivery. Furthermore, there was a significant interaction

between periconceptional alcohol exposure and hCG levels, with higher hCG levels

corresponding to a smaller effect of alcohol exposure at conception on gestational age at

delivery, indicating that hCG moderates the effect of alcohol on age at delivery (Supplementary

Table 3).

Since $_{HEa}$miRNAs collectively prevented trophoblast EMT, we hypothesized that, as a

functional consequence, these maternal miRNAs would also inhibit fetal growth. When we

delivered 8 out of the 11 $_{HEa}$miRNAs known to be present in mouse, to pregnant dams during

the period of placental branching morphogenesis and endometrial invasion , when EMT is

particularly active, we found that $_{HEa}$miRNAs reduced fetal growth. Importantly, ethanol

exposure during this period has also been shown to result in fetal growth deficits and

dysmorphia in rodent PAE models (89, 90) suggesting that maternal miRNA-mediated deficits in

trophoblast invasion may mediate some of the effects of PAE on fetal growth. In support of this,

we found placentas from the $_{HEa}$miRNA treated group had impaired expression of core EMT

pathway members. It is also feasible that $_{HEa}$miRNAs disrupt fetal growth through placental

vascular dynamics. The non-human primate tissue analyzed here was derived from animals that

were characterized in vivo using MRI and ultrasound imaging, which demonstrated that

maternal blood supply to the placenta was lower in ethanol-exposed animals compared to

controls, and that oxygen availability to the fetal vasculature was reduced (91). Thus, one

possibility is that compromised trophoblast invasion contributes to impaired maternal blood

flow in ethanol-exposed individuals, as we have also previously observed in mouse models (92).

Impaired nutrient uptake in the placenta, such as dysfunction in the amino acid, glucose,

and fatty acid transport systems have also been implicated in gestational pathologies, such as

intrauterine growth restriction (93). Furthermore, *in vitro* studies in trophoblasts have shown

alcohol exposure selectively impairs a subset of these amino acid and fatty acid transport

systems (94, 95) whilst *in vivo*, PAE in rodents alters expression of glucose transporters in the

late gestation placenta (23). These placental dysfunctions could also have insidious effects on

development that are not immediately detectable at birth. As an example, perturbations in

placental iron transport by PAE may impair central nervous system development during the

neonatal period, leading to cognitive deficits that last throughout adulthood (96, 97). Thus,

further investigation is warranted to determine if $_{HEa}$miRNAs contribute to this alcohol induced

impairment in trans-placental nutrient transport, and ultimately whether this impairment of

nutrient transport represents another avenue through which PAE disrupts fetal development.

It is likely that $_{HEa}$miRNAs may mediate other pregnancy associated pathologies, aside

from PAE. We identified numerous studies that reported increased circulating and placental

levels of at least 8 out of 11 $_{HEa}$miRNAs in gestational pathologies arising from placental

dysfunction. For example, elevated levels of one $_{HEa}$miRNA, miR-519a-3p, a member of the

placentally-expressed C19MC family cluster, was reported in placentae of patients with pre-

eclampsia, recurrent spontaneous abortion, and intrauterine growth restriction (40, 41, 54, 55).

Interestingly, collective overexpression of the 59 C19MC miRNAs inhibits trophoblast migration,

explaining their enrichment in the non-migratory villous trophoblasts and suggests their

downregulation is necessary for maturation into invasive extravillous trophoblasts (98). Thus, a

greater understanding of the placental roles of $_{HEa}$miRNAs may also help disentangle the

etiology of other pregnancy complications.

While our data suggest that the placenta is an important contributory source for

circulating $_{HEa}$miRNAs, the effects of $_{HEa}$miRNAs likely extend beyond the placenta into other

maternal tissues. Outside of the placenta, $_{HEa}$miRNAs may circulate in association with

lipoprotein complexes, or be encapsulated in extracellular vesicles (EVs) whose abundance

dramatically increases during pregnancy (99, 100). Recent work has demonstrated that

placental-derived EVs can regulate the maternal immune system as well as confer viral

resistance to recipient cells, including endothelial cells (101-104). Interestingly, other studies

also have identified endothelial cells as ready recipients for placental-derived EVs, suggesting

placental-EVs and their cargo miRNAs participate in synchronizing the growth of the placenta

with the accompanying maternal and fetal vascular remodeling (99, 105). While further

investigation is warranted into the role of EVs and miRNAs in maternal-fetal communication,

and to the extent they serve as paracrine/endocrine mediators for the placenta during

development, targeting $_{HEa}$miRNAs will likely have profound effects for both fetal and placental

development in the context of FASDs and other gestational pathologies.

While we did not investigate the effects of PAE on EMT in non-placental organs, it is

likely that PAE broadly disrupts EMT in multiple fetal compartments. Developmental ethanol

exposure has been shown inhibit the EMT-dependent migration of neural crest progenitors

involved in craniofacial development, explaining the facial dysmorphology seen in FAS and

FASDs (106, 107). Outside of its effects on the neural crest, PAE is significantly associated with

various congenital heart defects, including both septal defects and valvular malformations (108-

111). Septation of the heart, primarily atrial septation, is an EMT-dependent process, with

endocardial cells delaminating and transdifferentiating into mesenchymal cells that populate

the endocardial cushions as well as the muscular cap, which functions as the growing edge of

the muscular atrial septum(112, 113). The mesenchymal cells from the endocardial cushions

also form the cardiac valve progenitors. Thus, disruption of endocardial EMT could explain both

the valvular and septal malformation associated with PAE.

Collectively, our data on $_{HEa}$miRNAs suggest miRNA-based interventions could minimize

or reverse developmental effects of PAE and other placental-related pathologies. miRNA-based

therapeutic approaches have been advanced for other disease conditions. For example,

Miraversen[tm], an anti-miR-122 antisense oligonucleotide, has been shown to be effective in

reducing hepatitis-C viral burden (114). Additionally, a recent phase-1 clinical trial report

indicated that liposomal delivery of a tumor-suppressor miRNA was well tolerated in human

populations and showed evidence of therapeutic efficacy (115). However, we also observed

with $_{HEa}$miRNAs that the effects of combinations of miRNAs are not a sum of their individual

effects. Functional synergy between clusters of co-regulated miRNAs may be a common feature

in development and disease. For instance, in 2007, we presented early evidence that ethanol

exposure reduced miR-335, -21, and -153 in neural progenitors and that coordinate reduction

in these miRNAs yielded net resistance to apoptosis following ethanol exposure (116). In that

study, we also showed that coordinate knockdown of these three miRNAs was required to

induce mRNA for Jagged-1, a ligand for the Notch cell signaling pathway, an outcome that was

not recapitulated by knocking down each miRNA individually (116). More recently, combined

administration of miR-21 and miR-146a has been shown to be more effective in preserving

cardiac function following myocardial infarction than administration of either of these miRNAs

alone (117). While miRNA synergy has not been explored in detail, these data show that new

biology may emerge with admixtures of miRNAs, and that therapeutic interventions may

require the use of such miRNA admixtures rather than single miRNA molecules as have been

used in clinical studies to date. Our study was restricted to exploring the effects of the 11

$_{HEa}$miRNAs on development, which represent only the significantly increased fraction of miRNAs

elevated in the HEa group maternal plasma within our Ukrainian cohort. Indeed, the next 5

most elevated miRNAs are also abundantly expressed in the placenta (data not shown),

indicating they may also mediate the effects of PAE on placental biology.

In conclusion, we have observed how a set of 11 miRNAs, predictive of adverse infant

outcomes following PAE, collectively mediate the effects of alcohol on the placenta. Specifically,

elevated levels of these miRNAs promote an aberrant maturational phenotype in trophoblasts

by inhibiting core members of the EMT pathway and promoting syncytialization-dependent

hormone production. Functionally, these miRNAs are clinically correlated with measures of

fetal development and directly cause intrauterine growth restriction when administered in vivo.

Our work suggests that a greater understanding for the role of $_{HEa}$miRNAs during development,

and their role in coordinating the EMT pathway in the placenta and other developing tissues,

will benefit the understanding of FASDs and other gestational pathologies and potentially lead

to effective avenues for intervention.

Methods

<u>Mouse model of PAE:</u>

C57/BL6J mice (Jackson Laboratory, Bar Habor, ME) were housed under reverse 12-hour dark /

12-hour light cycle (lights off at 08:00 hours). PAE was performed using a previously described

limited access paradigm of maternal drinking (118, 119). Briefly, 60-day old female mice were

subjected to a ramp-up period with 0.066% saccharin containing 0% ethanol (2 days), 5%

ethanol (2 days), and finally 10% ethanol for 4-hours daily from 10:00–14:00 beginning 2 weeks

prior to pregnancy, continuing through gestation (Supplementary Figure 2A). Female mice

offered 0.066% saccharin without ethanol during the same time-period throughout pregnancy

served as controls. Tissue from the labyrinth, junctional, and decidual zone of male and female

gestational day 14 (GD14) placentae were microdissected, snap-frozen in liquid nitrogen, and

stored at -80ºC preceding RNA and protein isolation.

<u>Mouse model for _{HEa}miRNA overexpression:</u>

For systemic administration of miRNAs, previously nulliparous C57/BL6NHsd dams (Envigo,

Houston, TX) were tail-vein-injected on GD10 with either 50 μg of miRNA miRVana™ mimic

negative control (Thermo Fisher, Waltham, MA, Cat No. 4464061) or pooled _{HEa}miRNA

miRVana™ mimics in In-vivo RNA-LANCEr II (Bioo Scientific, Austin, TX, 3410-01), according to

manufacturer instructions. The 50 μg of pooled _{HEa}miRNA mimics consisted of equimolar

quantities of mmu-miR-222-5p, mmu-miR-187-5p, mmu-mir-299a, mmu-miR-491-3p, miR-760-

3p, mmu-miR-671-3p, mmu-miR-449a-5p, and mmu-miR-204-5p mimics. For bio-distribution

studies, 50 μg of pooled equimolar quantities of hsa-miR-519a-3p and hsa-miR-518f-3p mimics were

injected via tail vein. These human miRNAs were selected because no mouse homologs are known to

exist and consequently, estimates for organ distribution of exogenous miRNAs in the mouse are unlikely

to be contaminated by the expression of endogenous murine miRNAs. GD10 is a time point near the

beginning of the developmental period of branching morphogenesis, immediately following

chorioallantoic attachment, during which the placenta invades the maternal endometrium

(120). At GD18, pregnancies were terminated with subsequent quantification of fetal weight,

crown-rump length, snout-occipital distance, biparietal diameter, and placental weight (Figure

13A). Subsequently, tissue was snap-frozen in liquid nitrogen, and stored at -80°C preceding

RNA isolation.

Rat model of PAE:

Outbred nulliparous Sprague-Dawley rats were housed under a 12-hour light/12-hourdark

cycle. PAE in Sprague-Dawley was conducted according to our previously published exposure

paradigm (23, 121). Briefly, dams were given a liquid diet containing either 0% or 12.5% ethanol

(vol/vol) from 4 days prior to mating until GD4 (Supplementary Figure 2B). Dams had *ad libitum*

access to the liquid diet 21-hours daily and consumed equivalent calories. Water offered during

the remaining 3-hours of the day. On GD5, liquid diets were removed and replaced with

standard laboratory chow. On GD20, placentas were immediately separated into the labyrinth

and junctional zone, snap frozen in liquid nitrogen and stored at −80 °C preceding RNA

isolation.

Non-human primate model of PAE:

As previously described in detail (91), adult female rhesus macaques were trained to orally self-

administer either 1.5 g/kg/d of 4% ethanol solution (equivalent to 6 drinks/day), or an isocaloric

control fluid prior to time-mated breeding. Each pregnant animal continued ethanol exposure

until gestational day 60 (GD60, term gestation is 168 days in the rhesus macaque) (122).

Pregnancies were terminated by cesarean section delivery at three different time points; GD85,

GD110, or GD135 (Supplementary Figure 2C). The macaque placenta is typically bi-lobed with

the umbilical cord insertion in the primary lobe and bridging vessels supplying the fetal side

vasculature to the secondary lobe (Figure 2D showing gross placenta anatomy) (123) . Full

thickness tissue biopsies (maternal decidua to fetal membranes) were taken from both the

primary and secondary lobes of the placenta (Figure 2E showing H&E section of placenta).

Samples were immediately snap-frozen in liquid nitrogen and stored at -80°C preceding RNA

isolation.

<u>Cell culture trophoblast models:</u>

BeWO human cytotrophoblastic choriocarcinoma cells and HTR-8/SVneo extravillous cells were

sourced from ATCC (Manassas, VA, Cat No. CCL-98 and CRL-3271 respectively). BeWO cells

were maintained in HAM's F12 media containing penicillin (100 U/ml), streptomycin (100

µg/ml), and 10% vol/vol fetal calf serum (FCS) at 37°C and 5% CO_2. HTR8 cells were maintained

in RPMI-1640 media with 5% vol/vol FCS, under otherwise identical conditions. Culture medium

was replenished every 2 days and cells sub-cultured every 4-5 days.

BeWO cells were treated with 20 µm forskolin to induce syncytialization, as previously

described (124, 125). BeWO and HTR8 cells were also subjected to four separate ethanol

treatment conditions: 0 mg/dL, 60 mg/dl (13 mM),120 mg/dl (26 mM) or 320 mg/dl (70 mM).

To achieve $_{HEa}$miRNA overexpression and inhibition, Dharmacon miRIDIAN^{TM} miRNA mimics and

hairpin inhibitors [25 nM], or control mimic (Dharmacon, Lafeyette CO, Cat No. CN-001000-01-

05) and hairpin inhibitor (Dharmacon, Cat No. CN-001000-01-05) [25nm], were transfected into

subconfluent BeWO and HTR8 cells using RNAIMAX lipofection reagent (Thermo Fisher, Cat No.

13778).

<u>Cell cycle analysis:</u>

At 48-hours-post transfection, BeWO cells were pulsed with 10 μM EdU for 1-hour. Cells were

immediately harvested, and cell cycle analysis was performed with the Click-iT® EdU Alexa

Fluor® 488 Flow Cytometry Assay Kit (Thermo Fisher, Cat No. C10420), in conjunction with 7-

Amino-Actinomycin D (Thermo Fisher, Cat No. 00-6993-50), according to manufacturer

instructions, using the Beckman Coulter® Gallios 2/5/3 Flow Cytometer. Data was analyzed

using Kaluza software (Beckman Coulter, Brea, CA).

<u>Cell death analysis:</u>

BeWO cell culture was harvested 48-hours post transfection media was subjected to lactate

dehydrogenase (LDH) detection using the Pierce™ LDH Cytotoxicity Assay Kit (Thermo Fisher,

Cat No. 88953), according to manufacturer instructions, for lytic cell death quantification. The

Promega Caspase-Glo® 3/7 Assay Systems (Promega, Madison, WI, Cat No. G8091) was used to

quantify apoptotic cell death

Invasion assay:

At 24-hours post-transfection and/or ethanol exposure, HTR8 cells were serum starved for an

additional 18-hours. Subsequently, HTR8 cells were seeded onto trans-well permeable supports

precoated with 300 µg/mL Matrigel (Corning, Corning, NY, Cat No. 354248). After 24-hours,

cells remaining in the apical chamber were removed with a cotton swab. Cells that invaded into

the basal chamber were incubated with 1.2 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT) for 3-hours, and the precipitate solubilized with 10% SDS in

0.01N HCl. Absorbance intensities were read at 570 nm in a Tecan Infinite® 200 plate reader.

Metabolic flux analysis and calcium imaging:

BeWO cells (10,000/well) were plated into Seahorse XF96 Cell Culture Microplates (Agilent

Biotechnology, Cat No. 103275-100). The oxygen consumption rate (OCR), a measure of

mitochondrial respiration, and extracellular acidification rate (ECAR), a measure of glycolysis,

were measured using the Seahorse XFe96 flux analyzer (Seahorse Bioscience, North Billerica,

MA). At the time of assay, cell culture medium was replaced with the appropriate pre-warmed

Seahorse XF Base Medium (Agilent Biotechnology, Santa Clara, CA, Cat No. 102353-100). OCR

and ECAR parameters were measured using the Seahorse XFp Cell Energy Phenotype Test Kit[TM]

(Agilent Biotechnology, Cat No. 103275-100). Metabolic stress was induced by simultaneous

treatment with 1µm Oligomycin and 0.125µM Carbonyl cyanide p-[trifluoromethoxy]-phenyl-

hydrazone (FCCP).

BeWO cells were also plated onto glass coverslips in 24 well plates at a density of 30,000

cells/well. After exposure to ethanol and/or forskolin in culture, cells were prepared for calcium

imaging. After replacement of culture media with external imaging media (154 mM NaCl, 5 mM

KCl, 2 mM $CaCl_2$, 0.5 mM $MgCl_2$, 5 mM glucose, 10 mM HEPES, pH 7.4), cells were loaded for 35

minutes at 37°C with the calcium indicator dye fluo-4 AM (Thermo Fisher Scientific, Cat No.

F14201), at a final concentration of 5μM fluo-4 AM in 0.1% DMSO. After incubation, cells were

washed to remove remaining extracellular fluo-4 and imaged at 40x using confocal microscopy

(FV1200-equipped BX61WI microscope, Olympus Corporation, Center Valley, PA). Time-lapse

images were acquired at a frequency of 0.5Hz. Individual cells were manually outlined and area

and mean fluorescence intensity were obtained for each cell (FIJI image processing

package)(126) . To determine the functional calcium range of each cell, at the end of imaging,

cells were exposed to 5 μM ionomycin and 10 mM EGTA (0mM external Ca^{2+}, $F_{range} = F_{ionomycin}$-

F_{EGTA}). Baseline fluorescence was determined by averaging the lowest 5 consecutive

fluorescence values during the initial 5 minutes ($F_{baseline}$) which was then expressed as a

percentage of F_{range} ($\Delta F_{baseline} = (F_{baseline}-F_{EGTA})/F_{range}$ X100). Maximal intracellular calcium

response to 100 μM ATP was determined by averaging the highest 3 consecutive fluorescence

values during ATP application (F_{ATP}) and determining the amount of fluorescence as a

percentage of F_{range} ($\Delta F_{ATP} = (F_{ATP}-F_{EGTA})/F_{range}$ X100).

<u>Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis:</u>

Total RNA was extracted from tissue, well as BeWO and HTR8 cells, using the miRNeasy Mini kit

(Qiagen, Cat No. 217004). For miRNA qPCR assays, cDNA was synthesized from 200 ng of total

RNA using the miRCURY LNA Universal RT cDNA synthesis kit (Exiqon, Cat No. 203301/Qiagen,

Cat No. 339340, Germantown, MD) and expression was assessed using miRCURY LNA SYBR

Green (Exiqon, Cat No. 203401/Qiagen, Cat No. 339345). For mRNA qPCR assays, cDNA was

synthesized from 500 ng of total RNA using the qScript™ cDNA Synthesis Kit (Quanta/Qiagen,

Cat No. 95047). Gene expression analysis was performed using PerfeCTa SYBR Green FastMix

(Quanta, Cat No. 95073) on the ViiA 7 Real-Time PCR System (Thermo Fisher Scientific). The

data presented correspond to the mean $2^{-\Delta\Delta Ct}$ after being normalized to the geometric mean of

β-actin, Hypoxanthine-Guanine Phosphoribosyltransferase 1 (HPRT1), and 18s rRNA. Expression

data for miRNA was normalized to the geometric mean of miR-25-3p, miR-574-3p, miR-30b-5p,

miR-652-3p, and miR-15b-5p. For each primer pair, thermal stability curves were assessed for

evidence of a single amplicon and the length of each amplicon was verified using agarose gel

electrophoresis. A list of primers and their sequences is presented in Supplementary Table 1.

<u>Western immunoblotting analysis:</u>

Protein was extracted using 1X RIPA lysis buffer (Millipore Sigma, Burlington MA) supplemented

with Halt protease inhibitor cocktail (Thermo Fisher Scientific). Tissue was homogenized using

the Branson Sonifier 150. Protein concentration was determined using Pierce BCA protein assay

kit (Thermo Fisher Scientific) and 30 µg of protein was loaded onto a 4-12% Bis-Tris

(Invitrogen/Thermo Fisher Scientific, Cat No. NPO323BOX), size fractionated at 200 V for 35

minutes, and transferred to a PVDF membrane using the iBlot transfer system

(Invitrogen/Thermo Fisher Scientific). Blots with protein from cultured cells were blocked with

5% nonfat dry milk in tris-buffered saline containing Tween®-20 (TTBS) for 1-hour and

incubated overnight with primary antibody. The blot was then washed and incubated with an

HRP-conjugated goat anti-rabbit or anti-mouse IgG (Invitrogen) at dilution 1:1000 for 1-hour,

then developed using PerkinElmer Western Lightning Plus Chemi ECL (PerkinElmer; Waltham,

MA) and visualized using a CCD camera (Fluorchem Q, Alpha Innotech; San Leandro, CA). Blots

with protein from homogenized tissue were dried overnight, rehydrated in methanol, stained

with REVERT™ Total Protein Stain and developed with the Odyssey CLx Imaging System (LI-COR,

Lincoln, NE). Blots were then blocked with Odyssey® Blocking Buffer (TBS) for 1h and incubated

overnight with primary antibody. The blot was then washed and incubated with IRDye® 800CW

secondary antibody (LI-COR, Cat No. 925-32210). The following antibodies were used: β-Actin

HRP (Santa Cruz Biotechnology, Cat No. sc-47778); Goat anti-Mouse IgG (H+L) Secondary

Antibody, HRP (Thermo Fisher, Cat No. 62-6520); Goat anti-Rabbit IgG (H+L) Secondary

Antibody, HRP (Thermo Fisher, Cat No. 65-6120); purified Mouse Anti-E-Cadherin (BD

Biosciences, Cat No. 610181), Rabbit anti-vimentin antibody [EPR3776] (Abcam, Cat No. ab

924647). Protein levels were quantified using the densitometric analysis package in FIJI image

processing software (126).

<u>ELISA:</u>

The 2nd and 3rd trimester maternal plasma samples were collected as part of a longitudinal

cohort study conducted in two regions of Western Ukraine as part of the Collaborative Initiative

on Fetal Alcohol Spectrum Disorders (CIFASD.org) between the years 2006 and 2011, as

previously reported(11). Plasma, at a 1:1000 dilution, was subjected to hCG detection using

Abcam's intact human hCG ELISA kit (Cat no. ab100533) following the manufacturer's protocol.

<u>Literature Review</u>

We conducted a literature review for _{HEa}miRNAs and their associated gestational pathology

using the National Institute of Health's Pubmed search interface. For each miRNA, the following

search parameters were used:

756   *[miRX OR miR X OR miRNA X OR miRNAX or miRNX] AND MeSH Term*

where X represents the miRNA of interest and automatic term expansion was enabled. The

following MeSH terms, and related search terms (in brackets), were used: Fetal Growth

Retardation [Intrauterine Growth Retardation, IUGR Intrauterine Growth Restriction, Low Birth

Weight, LBW, Small For Gestational Age, SGA], Premature Birth [Preterm Birth, Preterm Birth,

Preterm Infant, Premature Infant, Preterm Labor, Premature Labor], Spontaneous Abortion

[Early Pregnancy Loss, Miscarriage, Abortion, Tubal Abortion, Aborted Fetus], Pre-Eclampsia

[Pre Eclampsia, Preeclampsia, Pregnancy Toxemia, Gestational Hypertension, Maternal

Hypertension], and Maternal Exposure [Environmental Exposure, Prenatal Exposure]. Returned

articles were subsequently assessed for relevance.

<u>Secondary analysis of RNA sequencing data:</u>

Expression levels of _{HEa}miRNAs in tissues were determined using the Human miRNA Expression

Database and the miRmine Human miRNA expression database(66, 127). For expression

analysis of _{HEa}miRNA pri-miRNAs, RNA sequencing data was used from NCBI's sequence read

archive (https://www.ncbi.nlm.nih.gov/sra). The accession numbers for the sequence files are:

uterus (SRR1957209), thyroid (SRR1957207), thymus (SRR1957206), stomach (SRR1957205),

spleen (SRR1957203), small intestine (SRR1957202), skeletal muscle (SRR1957201), salivary

gland (SRR1957200), placenta (SRR1957197), lung (SRR1957195), liver (SRR1957193), kidney

(SRR1957192), heart (SRR1957191), whole brain (SRR1957183), adrenal gland (SRR1957124),

bone marrow (ERR315396), colon (ERR315484), adipose tissue (ERR315332), and pancreas

(ERR315479). Deep sequencing analysis was conducted using the Galaxy version 15.07 user

interface according to the bioinformatics pipeline outlined in Supplementary Figure 1.

<u>Statistical analyses:</u>

Linear regression models were used to estimate associations between infant growth measures

and miRNA expression levels, gestational age at blood draw, the interaction between subject-

centered miRNA expression level and gestational age at blood draw, and child sex. Spearman

correlations between infant growth measures and subject-centered miRNA expression levels

were also calculated. Linear regression models were also used to estimate the associations

between gestational at birth and log-transformed hCG levels, ethanol intake, the interaction

between log-transformed hCG levels and ethanol intake, gestational at blood draw, and child

sex. Statistical Analysis and graphs were generated with GraphPad Prism 6 software (GraphPad

Software, Inc., La Jolla, CA), SPSS v24, or R version 3.3.1. Results are expressed as the mean ±

SEM, or alternatively as box-and-whisker plots with the bounds of the box demarcating limits of

1st and 3rd quartile, a median line in the center of the box, and whiskers representing the total

range of data. The overall group effect was analyzed for significance using 1-way MANOVA, 1-

way or 2-way ANOVA with Tukey's Honest Significance Difference (HSD) post-hoc testing when

appropriate (i.e. following a significant group effect in 1-way ANOVA or given a significant

interaction effect between experimental conditions in 2-way ANOVA), to correct for a family-

wise error rate. A 2-tailed Student's t-test was used for planned comparisons. For experiments

characterizing the individual effects of $_{HEa}$miRNAs against the control miRNA or antagomirs,

individual 2-tailed Student's t-test with 5% FDR correction was applied to account for multiple

comparisons. All statistical tests, sample-sizes, and post-hoc analysis are appropriately reported

in the results section. A value of $p < 0.05$ was considered statistically significant, and a value of

$0.1 < p < 0.05$ was considered marginally significant.

<u>Study approval:</u>

Human study protocols were approved by Institutional Review Boards at the Lviv National

Medical University, Ukraine, and the University of California San Diego as well as Texas A&M

University in the USA. Research was conducted according to the principles expressed in the

Declaration of Helsinki with written informed consent received from participants prior to

inclusion in the study. All rodent experiments were performed in accordance with protocols

approved by the University of New Mexico Institutional Animal Care and Use Committee

(IACUC), and the Texas A&M University IACUC. All procedures involving non-human primate

research subjects were approved by the IACUC of the Oregon National Primate Research Center

(ONPRC), and guidelines for humane animal care were followed. The ONPRC abides by the

Animal Welfare Act and Regulations enforced by the US Department of Agriculture.

<u>Author contributions:</u>

AT, RM and CC conceived of and planned the study. AT, AM, and NS designed and conducted

cell culture studies, and AT conducted in vivo, murine miRNA overexpression studies and

analyzed tissues from mouse, rat and primate PAE models. AA developed the mouse PAE model

Table 1

MIMAT #	miRNA	Trimester	Weight			Height			Head Circumference		
			Sig.	R²	ρ	Sig.	R²	ρ	Sig.	R²	ρ
MIMAT0004569	hsa-miR-222-5p	2	0.821	1.224	-0.051	0.066	9.572	-0.179	0.8	1.732	-0.104
MIMAT0004561	hsa-miR-187-5p	2	0.462	6.347	0.068	0.17	12.607	-0.074	0.134	10.903	0.103
MIMAT0000687	hsa-mir-299-3p	2	0.552	1.113	0.029	0.069	9.299	-0.203	0.036*	8.65	0.1
MIMAT0004765	hsa-miR-491-3p	2	0.172	3.61	0.112	0.849	2.033	-0.055	0.024*	12.529	0.156
MIMAT0004948	hsa-miR-885-3p	2	0.142	4.227	-0.174	0.044*	7.667	-0.231	0.59	1.36	-0.115
MIMAT0002842	hsa-miR-518f-3p	2	0.246	2.517	0.134	0.918	2.134	-0.118	0.007**	14.561	0.219
MIMAT0004957	hsa-miR-760	2	0.059	6.314	0.195	0.22	4.096	0.079	0.055	10.158	0.195
MIMAT0003880	hsa-miR-671-5p	2	0.123	7.24	0.11	0.578	5.264	-0.031	0.073	10.794	0.107
MIMAT0001541	hsa-miR-449a	2	0.101	11.584	0.104	0.718	5.851	-0.072	0.173	10.036	0.068
MIMAT0000265	hsa-miR-204-5p	2	0.026*	12.377	0.184	0.272	4.973	0	0.131	7.095	0.108
MIMAT0002869	hsa-miR-519a-3p	2	0.034*	7.975	0.153	0.403	6.83	-0.012	0.093	8.181	0.096
MIMAT0004569	hsa-miR-222-5p	3	0.875	0.993	-0.046	0.018*	10.709	-0.196	0.577	4.696	-0.01
MIMAT0004561	hsa-miR-187-5p	3	0.538	2.055	0.049	0.37	2.029	-0.109	0.784	3.697	0.002
MIMAT0000687	hsa-mir-299-3p	3	0.511	0.762	0.005	0.514	1.769	-0.072	0.87	3.786	-0.077
MIMAT0004765	hsa-miR-491-3p	3	0.824	3.165	-0.028	0.2	12.122	-0.121	0.747	4.188	-0.081
MIMAT0004948	hsa-miR-885-3p	3	0.807	0.148	0.029	0.102	4.686	-0.156	0.376	5.009	0.032
MIMAT0002842	hsa-miR-518f-3p	3	0.515	2.099	0.109	0.421	1.715	0.016	0.245	7.917	0.152
MIMAT0004957	hsa-miR-760	3	0.368	1.396	0.141	0.761	0.716	-0.022	0.207	6.052	0.172
MIMAT0003880	hsa-miR-671-5p	3	0.055	8.715	0.155	0.367	3.521	-0.133	0.076	8.196	0.15
MIMAT0001541	hsa-miR-449a	3	0.995	0.085	-0.06	0.982	0.678	-0.151	0.026*	12.022	0.135
MIMAT0000265	hsa-miR-204-5p	3	0.019*	11.872	0.23	0.206	5.589	0.022	0.002**	18.683	0.319
MIMAT0002869	hsa-miR-519a-3p	3	0.391	2.82	0.043	0.302	5.917	-0.151	0.106	9.286	0.118

Table 1: HEamiRNAs are significantly correlated with independent measures of infant size

The correlation of 2nd and 3rd trimester maternal plasma HEamiRNA levels with independent measures of infant size. HEamiRNAs and their significantly correlated sex and gestational age-adjusted growth parameters appear in red. *p<0.05, **p<0.01.

 Figures

Figure 1

Figure 1: $_{HEa}$**miRNAs are placentally enriched and associated with gestational pathologies**

1A) Venn diagram on number of $_{HEa}$miRNAs reported to be associated with alcohol or other

prenatal exposures.

1B) Venn diagram on number of $_{HEa}$miRNAs reported to be associated with different gestational

pathologies. Inset colored circles represent the corresponding sex and gestational age-adjusted

growth parameters these miRNAs were correlated with. Of the 22 studies queried, 11 (50%)

utilized unbiased screenings for miRNA expression.

1C) Heatmap of mature $_{HEa}$miRNA expression and 1D) pri-$_{HEa}$miRNA expression across different

tissues resulting from secondary analysis of publicly available RNA-sequencing data. Legend

depicts row-centered Z-score.

Figure 2

Figure 2: $_{HEa}$miRNAs mediate the effect of PAE on EMT pathway members in mouse and macaque placentas.

2A) Histological image of GD14 mouse placenta. Outlined in red is the labyrinth zone, blue is the junctional zone, black is the decidual zone. Inset is a high magnification image of the labyrinth zone.

2B) MANOVA of gene expression of core EMT pathway members in different regions of the mouse placenta in control and PAE mice (n=29 samples).

2C) MANCOVA of gene expression of core EMT pathway members in the mouse placental labyrinth zone before (Basic Model) and after accounting for the expression of $_{HEa}$miRNAs (n=29 samples).

2D) Gross anatomy photograph of the primary (left) and secondary (right) lobes of a GD135 macaque placenta. Outlined in red is an individual cotyledon from the secondary lobe. Inset is a full thickness hematoxylin and eosin stained histological section of a representative cotyledon with the fetal membranes outlined in black, villous tissue outlined in red and maternal decidua in blue.

2E) MANCOVA of gene expression of core EMT pathway members in placental cotyledons of PAE and control macaques, accounting for the expression of $_{HEa}$miRNAs collectively (n=23 samples).

2F) MANCOVA of gene expression of core EMT pathway members in macaque placentas after accounting for expression of $_{HEa}$miRNAs individually (n=23 samples).

Figure 3

Figure 3: PAE interferes with EMT pathway member expression in mouse and macaque placentas

Expression of 3A) *CDH1*, 3B) *VIM*, 3C) *SNAI1*, 3D) *TWIST*, and 3E) *SNAI2* in the placental labyrinth zone of PAE and control mice (n=5-12 samples per group).

3F) Densitometric quantification of E-Cadherin expression in the labyrinth zone of PAE and control mice as well as representative blot of E-Cadherin expression (top) and total protein expression (bottom, n=5-12 samples per group).

Expression of 3G) *CDH1*, 3H) *VIM*, 3I) *SNAI2*, and 3J) *TWIST* transcripts in PAE and Control macaque placental cotyledons (n=3-5 samples per group).

Results are expressed as the mean ± SEM, LDR=Molecular Weight Ladder; ANOVA: significant main effect of PAE [$^{\varepsilon}$p<0.05, $^{\varepsilon\varepsilon\varepsilon}$p<0.001], significant interaction effect (sex by PAE, [†p<0.05]).

For post-hoc analysis, ***p<0.001 by Tukey's HSD.

Figure 4

Figure 4: HEamiRNAs interfere with EMT pathway member expression in BeWO

cytotrophoblasts

Expression of 4A) *CDH1,* 4B) *VIM,* 4C) *TWIST,* and 4D) *SNAI1* transcripts 4E) and densitometric quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following HEamiRNAs or control miRNA overexpression with or without concomitant 320 mg/dL ethanol exposure.

4F) Expression of *CDH1,* 4G) *VIM,* 4H) *TWIST,* and 4I) *SNAI1* transcripts 4J) and densitometric quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following HEamiRNAs or control hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol exposure. Results are expressed as the mean ± SEM, LDR=Molecular Weight Ladder, n=10 samples per group; ANOVA: significant main effect of HEamiRNA transfection [####p<0.0001], significant interaction effect (HEamiRNA by 320mg/dL ethanol, [†p<0.05, †††p<0.001]). For post-hoc analysis *p<0.05, **p<0.01 by Tukey's HSD.

Figure 5

Figure 5: _{HEa}miRNAs interfere with EMT pathway member expression in HTR8 extravillous trophoblasts

Expression of 5A) *SNAI2* 5B) *VIM* 5C) *TWIST* and 5D) *SNAI1* transcripts 5E) as well as densitometric quantification of Vimentin protein levels in HTR8 extravillous trophoblasts following _{HEa}miRNAs or control miRNA overexpression with or without concomitant 320 mg/dL ethanol exposure.

Expression of 5F) *SNAI2* 5G) *VIM* 5H) *TWIST* and 5I) *SNAI1* transcripts 5J) as well as densitometric quantification of Vimentin protein levels in HTR8 extravillous trophoblasts following _{HEa}miRNA or control hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol exposure.

Results are expressed as the mean ± SEM, LDR=Molecular Weight Ladder, n=10 samples per group; ANOVA: significant main effect of _{HEa}miRNA transfection [##p<0.01, ####p<0.0001], significant main effect of 320mg/dL ethanol exposure [εεp<0.01], significant interaction effect (_{HEa}miRNA by 320mg/dL ethanol, [†p<0.05, ††p<0.01]). For post-hoc analysis *p<0.05, **p<0.01, ***p<0.001, and ***p<0.0001 by Tukey's HSD.

Figure 6

Figure 6: Antagomirs prevent HEamiRNA induced impairment of EMT core pathway members

Expression of 6A) *CDH1* 6B) *VIM* 6C) *TWIST* and 6D) *SNAI1* Transcripts following control or HEamiRNA hairpin inhibitor transfection followed by control or HEamiRNA overexpression in BeWO cytotrophoblasts.

Expression of 6E) *CDH1* 6F) *VIM* 6G) *TWIST* and 6H) *SNAI1* Transcripts following control or HEamiRNA antagomir transfection followed by control or HEamiRNA overexpression in HTR8 extravillous trophoblasts.

In subheadings: **C** denotes control miRNA mimic or hairpin whereas **T** denotes HEamiRNA mimic or hairpin inhibitor. Results are expressed as expressed as the mean ± SEM, n=10 samples per group; ANOVA: significant treatment effect [##p<0.01, ###p<0.001, ####p<0.0001]. For post-hoc analysis, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by Tukey's HSD.

Figure 7

Figure 7: ₍HEₐ₎miRNA impair extravillous trophoblast invasion

923 Transwell invasion of HTR8 extravillous trophoblasts following transfection with 7A) ₍HEₐ₎miRNA

924 mimics or 7B) hairpin inhibitors with or without concomitant 320 mg/dL ethanol exposure.

925 Results are expressed as expressed as the mean ± SEM; n=10 samples per group; *p<0.05 by

926 Unpaired T-test

Figure 8

Figure 8: HEamiRNA cause cell cycle retardation in trophoblasts

8A) Degree of EdU incorporation following control and $_{HEa}$miRNA overexpression or 8B) control and $_{HEa}$miRNA hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol exposure in BeWO cytotrophoblasts. Results are expressed as expressed as the mean ± SEM. 8C) Box and whisker plot for the proportion of cells in G_0/G_1, S, or G_2/M phase of the cell cycle following control and $_{HEa}$miRNA overexpression or 8D) control and $_{HEa}$miRNA hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol exposure. Bounds of box demarcate limits of 1st and 3rd quartile, line in middle is the median, and whiskers represent the range of data. Representative flow cytometry experiment images are shown on the right. n=10 samples per group; ANOVA: significant main effect of $_{HEa}$miRNA transfection [##p<0.01, ###p<0.001, and ####p<0.0001].

Figure 9

942
Figure 9: Antagomirs prevent _{HEa}miRNA induced cell cycle retardation
9A) Degree of EdU incorporation following control or $_{HEa}$miRNA hairpin inhibitor transfection
followed by control or $_{HEa}$miRNA overexpression in BeWO cytotrophoblasts. Results are
expressed as expressed as the mean ± SEM.
9B) Box and whisker plot for the proportion of cells in G_0/G_1, S, or G_2/M phase of the cell cycle
following control or $_{HEa}$miRNA hairpin inhibitor transfection followed by control or $_{HEa}$miRNA
overexpression in BeWO cytotrophoblasts. Bounds of box demarcate limits of 1st and 3rd
quartile, line in middle is the median, and whiskers represent the range of data. Representative
flow cytometry experiment images are shown on the right.
In subheadings: **C** denotes control miRNA mimic or hairpin whereas **T** denotes $_{HEa}$miRNA mimic
or hairpin inhibitor. n=5 samples per group; ANOVA: significant treatment effect [###p<0.001].
For post-hoc analysis, **p<0.01 by Tukey's HSD.
955
956
957

Figure 10

Figure 10: $_{HEa}$miRNAs modulate differentiation-associated Ca^{2+} dynamics but have minimal

effect on the cellular energetics profile

10A) Time-lapse confocal images of BeWO cytotrophoblasts loaded with fluo-4 Ca^{2+} indicator

dye under indicated treatment conditions. Arrowhead indicates a fused, multinuclear cell, scale

bar is 50µm.

10B) Box and whisker plot of intracellular calcium levels following acute ATP administration in

BeWO cytotrophoblasts with control and $_{HEa}$miRNA overexpression with or without concomitant

320 mg/dL ethanol exposure. Bounds of box demarcate limits of 1st and 3rd quartile, line in

middle is the median, and whiskers represent the range of data.

10C) Box and whisker plot of intracellular calcium levels following acute ATP administration in

BeWO cytotrophoblasts with control and $_{HEa}$miRNA overexpression with or without 20 µm

forskolin treatment.

10D) Baseline oxygen consumption rate (OCR), 10E) baseline extracellular acidification rate

(ECAR), 10F) stressed OCR, and 10G) stressed ECAR in BeWO cytotrophoblasts with control and

$_{HEa}$miRNA overexpression with or without concomitant 320mg/dL ethanol exposure. Metabolic

stress was induced by treatment with 1µm Oligomycin and 0.125µM (FCCP). Results are

expressed as expressed as the mean ± SEM.

n=10 samples per group; ANOVA: significant main effect of 320mg/dL ethanol exposure

[$^{\varepsilon}$p<0.05, $^{\varepsilon\varepsilon\varepsilon}$p<0.001], significant interaction effect ($_{HEa}$miRNA by 320mg/dL ethanol, [†p<0.05,

††p<0.01, and ††††p<0.0001]). For post-hoc analysis, *p<0.05, **p<0.01, ***p<0.001, and

***p<0.0001 by Tukey's HSD.

Figure 11

980
Figure 11: HEamiRNAs promote syncytialization dependent hCG production
Expression of 11A) *CGA,* 11B) *CGB,* 11C) *IGF2,* and 11D) *CDH1* transcripts 11E) and
densitometric quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following
HEamiRNAs or control miRNA overexpression with or without 20 μm forskolin treatment.
Expression of 11F) *CGA*, 11G) *CGB*, 11H) *IGF2,* and 11I) *CDH1* transcripts 11J) and
densitometric quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following
HEamiRNAs or control hairpin inhibitor transfection with or without 20 μm forskolin treatment.
Results are expressed as expressed as the mean ± SEM, LDR=Molecular Weight Ladder, n=10
samples per group; ANOVA: significant main effect of HEamiRNA transfection [####$p<0.0001$],
significant interaction effect (HEamiRNA by 320mg/dL ethanol, [†$p<0.05$]). For post-hoc analysis,
*$p<0.05$, **$p<0.01$ by Tukey's HSD.
992
993

Figure 12

Figure 12: PAE elevates 3ʳᵈ trimester maternal hCG

Box and whisker plot of 2ⁿᵈ and 3ʳᵈ trimester maternal hCG levels in UE, HEua, and HEa group
mothers of our Ukrainian birth cohort. Bounds of box demarcate limits of 1st and 3rd quartile,
line in middle is the median, and whiskers represent the range of data. Results are expressed as
expressed as the mean ± SEM, n=22-23 samples per group; *p=0.03 (Mood's Median Test,
χ^2=7.043, df=2).

1003

Figure 13: HEamiRNAs restrict fetal growth

13A) Schematic for measures of crown rump length (CRL), biparietal diameter (BPD), and snout-occipital distance (SOD).

13B) Fetal weight, 13C) crown-rump length, 13D) biparietal diameter, 13E) snout-occipital distance, 13F) and placental weight at GD18 following administration of control (Ctrl) and HEamiRNA mimics to pregnant C57/Bl6 dams on GD10. Dots represent median measures of fetal size and placental weights from male and female offspring in independent litters. There were no significant differences in litter sizes [Ctrl: 8.2 and HEamiRNAs: 8.5] or sex ratios [Ctrl: 0.86 and HEamiRNAs: 1.21] between treatment conditions (p>0.5 for all measures).

Results are expressed as expressed as the mean ± SEM, n=5-6 separate litters per treatment condition; ANOVA: significant main effect of HEamiRNA administration [#p<0.05 and ##p<0.01].

Figure 14

1017

Figure 14: _{HEa}miRNAs interfere with core EMT pathway members in the placenta

Expression of 14A) *CDH1* 14B) *VIM* 14C) *TWIST* 14D) *SNAI1* and 14E) *SynB* transcripts in GD18 placenta following administration of control (Ctrl) and _{HEa}miRNA mimics to pregnant C57/Bl6 dams on GD10.

Dots represent median expression values of male and female offspring in independent litters. Results are expressed as expressed as the mean ± SEM, n=5-6 separate litters per treatment condition, ANOVA: significant main effect of _{HEa}miRNA administration [#p<0.05, ###p<0.001], significant interaction effect (fetal sex by _{HEa}miRNA administration, [†p<0.05]). For post-hoc analysis, *p<0.05 by Tukey's HSD.

1027
1028
1029

References

References

1.   ACOG. Committee opinion no. 496: At-risk drinking and alcohol dependence: obstetric and
gynecologic implications. *Obstetrics and gynecology.* 2011;118(2 Pt 1):383-8.

2.   Popova S, Lange S, Probst C, Gmel G, and Rehm J. Estimation of national, regional, and global
prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and
meta-analysis. *The Lancet Global Health.* 2017;5(3):e290-e9.

3.   SAMHSA. The NSDUH Report: 18 percent of pregnant women drink alcohol during early
pregnancy. *NSDUH Report.* 2013.

4.   Bakhireva LN, Sharkis J, Shrestha S, Miranda-Sohrabji TJ, Williams S, and Miranda RC. Prevalence
of Prenatal Alcohol Exposure in the State of Texas as Assessed by Phosphatidylethanol in
Newborn Dried Blood Spot Specimens. *Alcohol Clin Exp Res.* 2017;41(5):1004-11.

5.   Riley EP, Infante MA, and Warren KR. Fetal alcohol spectrum disorders: an overview.
Neuropsychol Rev. 2011;21(2):73-80.

6.   May PA, Gossage JP, Kalberg WO, Robinson LK, Buckley D, Manning M, et al. Prevalence and
epidemiologic characteristics of FASD from various research methods with an emphasis on
recent in-school studies. *Developmental disabilities research reviews.* 2009;15(3):176-92.

7.   May PA, Blankenship J, Marais AS, Gossage JP, Kalberg WO, Barnard R, et al. Approaching the
prevalence of the full spectrum of fetal alcohol spectrum disorders in a South African
population-based study. *Alcohol Clin Exp Res.* 2013;37(5):818-30.

8.   Popova S, Lange S, Probst C, Gmel G, and Rehm J. Estimation of national, regional, and global
prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and
meta-analysis. *Lancet Glob Health.* 2017;5(3):e290-e9.

9.   Roozen S, Peters GJ, Kok G, Townend D, Nijhuis J, and Curfs L. Worldwide Prevalence of Fetal
Alcohol Spectrum Disorders: A Systematic Literature Review Including Meta-Analysis. *Alcohol
Clin Exp Res.* 2016;40(1):18-32.

10.   Popova S, Lange S, Burd L, and Rehm J. The Economic Burden of Fetal Alcohol Spectrum Disorder
in Canada in 2013. *Alcohol and Alcoholism.* 2016;51(3):367-75.

11.   Balaraman S, Schafer JJ, Tseng AM, Wertelecki W, Yevtushok L, Zymak-Zakutnya N, et al. Plasma
miRNA Profiles in Pregnant Women Predict Infant Outcomes following Prenatal Alcohol
Exposure. *PLoS One.* 2016;11(11):e0165081.

12.   Rossant J, and Cross JC. Placental development: Lessons from mouse mutants. *Nature Reviews
Genetics.* 2001;2:538.

13.   E. Davies J, Pollheimer J, Yong HEJ, Kokkinos MI, Kalionis B, Knöfler M, et al. Epithelial-
mesenchymal transition during extravillous trophoblast differentiation. *Cell Adhesion &
Migration.* 2016;10(3):310-21.

14.   Zhou Y, Damsky CH, and Fisher SJ. Preeclampsia is associated with failure of human
cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular
invasion in this syndrome? *The Journal of Clinical Investigation.* 1997;99(9):2152-64.

15.   Damsky CH, and Fisher SJ. Trophoblast pseudo-vasculogenesis: faking it with endothelial
adhesion receptors. *Current opinion in cell biology.* 1998;10(5):660-6.

16.   Brown LM, Lacey HA, Baker PN, and Crocker IP. E-cadherin in the assessment of aberrant
placental cytotrophoblast turnover in pregnancies complicated by pre-eclampsia. *Histochemistry
and cell biology.* 2005;124(6):499-506.

17.   Fedorova L, Gatto-Weis C, Smaili S, Khurshid N, Shapiro JI, Malhotra D, et al. Down-regulation of
the transcription factor snail in the placentas of patients with preeclampsia and in a rat model of
preeclampsia. *Reprod Biol Endocrinol.* 2012;10:15.

18.   Blechschmidt K, Mylonas I, Mayr D, Schiessl B, Schulze S, Becker KF, et al. Expression of E-
1077   cadherin and its repressor snail in placental tissue of normal, preeclamptic and HELLP
1078   pregnancies. *Virchows Archiv : an international journal of pathology.* 2007;450(2):195-202.
1079   19.   Du L, Kuang L, He F, Tang W, Sun W, and Chen D. Mesenchymal-to-epithelial transition in the
1080   placental tissues of patients with preeclampsia. *Hypertension research : official journal of the
1081   Japanese Society of Hypertension.* 2017;40(1):67-72.
1082   20.   Gundogan F GJ, Ooi JH, Sung J, Qi W, et al. Dual Mechanisms of Ethanol-Impaired Placentation:
1083   Experimental Model. *J Clin Exp Pathol.* 2013:3:142. doi: 10.4172/2161-0681.1000142.
1084   21.   Tai M, Piskorski A, Kao JCW, Hess LA, M. de la Monte S, and Gündoğan F. Placental Morphology
1085   in Fetal Alcohol Spectrum Disorders. *Alcohol and Alcoholism.* 2017;52(2):138-44.
1086   22.   Gundogan F, Gilligan J, Qi W, Chen E, Naram R, and de la Monte SM. DOSE EFFECT OF
1087   GESTATIONAL ETHANOL EXPOSURE ON PLACENTATION AND FETAL GROWTH. *Placenta.*
1088   2015;36(5):523-30.
1089   23.   Gardebjer EM, Cuffe JS, Pantaleon M, Wlodek ME, and Moritz KM. Periconceptional alcohol
1090   consumption causes fetal growth restriction and increases glycogen accumulation in the late
1091   gestation rat placenta. *Placenta.* 2014;35(1):50-7.
1092   24.   Kalisch-Smith JI, Outhwaite JE, Simmons DG, Pantaleon M, and Moritz KM. Alcohol exposure
1093   impairs trophoblast survival and alters subtype-specific gene expression in vitro. *Placenta.*
1094   2016;46:87-91.
1095   25.   Bahado-Singh RO, Oz AU, Kingston JM, Shahabi S, Hsu CD, and Cole L. The role of
1096   hyperglycosylated hCG in trophoblast invasion and the prediction of subsequent pre-eclampsia.
1097   *Prenatal diagnosis.* 2002;22(6):478-81.
1098   26.   Muller F, Savey L, Le Fiblec B, Bussieres L, Ndayizamba G, Colau JC, et al. Maternal serum human
1099   chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. *Am J Obstet
1100   Gynecol.* 1996;175(1):37-40.
1101   27.   Spencer K, Macri JN, Aitken DA, and Connor JM. Free beta-hCG as first-trimester marker for fetal
1102   trisomy. *Lancet (London, England).* 1992;339(8807):1480.
1103   28.   Spencer K. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its
1104   potential value in screening for Down's syndrome. *Clin Chem.* 1991;37(6):809-14.
1105   29.   Tsamou M, Vrijens K, Madhloum N, Lefebvre W, Vanpoucke C, and Nawrot TS. Air pollution-
1106   induced placental epigenetic alterations in early life: a candidate miRNA approach. *Epigenetics.*
1107   2018;13(2):135-46.
1108   30.   Shi Z, Zhao C, Guo X, Ding H, Cui Y, Shen R, et al. Differential expression of microRNAs in omental
1109   adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of
1110   ERalpha expression in estrogen-induced insulin resistance. *Endocrinology.* 2014;155(5):1982-90.
1111   31.   McAdams RM, McPherson RJ, Beyer RP, Bammler TK, Farin FM, and Juul SE. Dose-dependent
1112   effects of morphine exposure on mRNA and microRNA (miR) expression in hippocampus of
1113   stressed neonatal mice. *PLoS One.* 2015;10(4):e0123047.
1114   32.   Ignacio C, Mooney SM, and Middleton FA. Effects of Acute Prenatal Exposure to Ethanol on
1115   microRNA Expression are Ameliorated by Social Enrichment. *Frontiers in pediatrics.* 2014;2:103.
1116   33.   Liu XD, Wu X, Yin YL, Liu YQ, Geng MM, Yang HS, et al. Effects of dietary L-arginine or N-
1117   carbamylglutamate supplementation during late gestation of sows on the miR-15b/16, miR-
1118   221/222, VEGFA and eNOS expression in umbilical vein. *Amino acids.* 2012;42(6):2111-9.
1119   34.   Nemoto T, Kakinuma Y, and Shibasaki T. Impaired miR449a-induced downregulation of Crhr1
1120   expression in low-birth-weight rats. *The Journal of endocrinology.* 2015;224(2):195-203.
1121   35.   Nardelli C, Granata I, Iaffaldano L, D'Argenio V, Del Monaco V, Maruotti GM, et al. miR-138/miR-
1122   222 Overexpression Characterizes the miRNome of Amniotic Mesenchymal Stem Cells in
1123   Obesity. *Stem cells and development.* 2017;26(1):4-14.

1124   36.   Baker BC, Mackie FL, Lean SC, Greenwood SL, Heazell AEP, Forbes K, et al. Placental dysfunction
1125   is associated with altered microRNA expression in pregnant women with low folate status.
1126   *Molecular nutrition & food research.* 2017;61(8).
1127   37.   Salihu HM, Kornosky JL, Lynch O, Alio AP, August EM, and Marty PJ. Impact of prenatal alcohol
1128   consumption on placenta-associated syndromes. *Alcohol.* 2011;45(1):73-9.
1129   38.   Khong TY. Placental vascular development and neonatal outcome. *Seminars in neonatology : SN.*
1130   2004;9(4):255-63.
1131   39.   Ray JG, Vermeulen MJ, Schull MJ, and Redelmeier DA. Cardiovascular health after maternal
1132   placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet (London,*
1133   *England).* 2005;366(9499):1797-803.
1134   40.   Wang D, Na Q, Song WW, and Song GY. Altered Expression of miR-518b and miR-519a in the
1135   placenta is associated with low fetal birth weight. *American journal of perinatology.*
1136   2014;31(9):729-34.
1137   41.   Wang JM, Gu Y, Zhang Y, Yang Q, Zhang X, Yin L, et al. Deep-sequencing identification of
1138   differentially expressed miRNAs in decidua and villus of recurrent miscarriage patients. *Archives*
1139   *of gynecology and obstetrics.* 2016;293(5):1125-35.
1140   42.   Hromadnikova I, Kotlabova K, Ondrackova M, Pirkova P, Kestlerova A, Novotna V, et al.
1141   Expression profile of C19MC microRNAs in placental tissue in pregnancy-related complications.
1142   *DNA and cell biology.* 2015;34(6):437-57.
1143   43.   Hromadnikova I, Kotlabova K, Ivankova K, and Krofta L. Expression profile of C19MC microRNAs
1144   in placental tissue of patients with preterm prelabor rupture of membranes and spontaneous
1145   preterm birth. *Molecular medicine reports.* 2017;16(4):3849-62.
1146   44.   Timofeeva AV, Gusar VA, Kan NE, Prozorovskaya KN, Karapetyan AO, Bayev OR, et al.
1147   Identification of potential early biomarkers of preeclampsia. *Placenta.* 2018;61:61-71.
1148   45.   Dong F, Zhang Y, Xia F, Yang Y, Xiong S, Jin L, et al. Genome-wide miRNA profiling of villus and
1149   decidua of recurrent spontaneous abortion patients. *Reproduction (Cambridge, England).*
1150   2014;148(1):33-41.
1151   46.   Hu Y, Li P, Hao S, Liu L, Zhao J, and Hou Y. Differential expression of microRNAs in the placentae
1152   of Chinese patients with severe pre-eclampsia. *Clinical chemistry and laboratory medicine.*
1153   2009;47(8):923-9.
1154   47.   Murphy MS, Casselman RC, Tayade C, and Smith GN. Differential expression of plasma
1155   microRNA in preeclamptic patients at delivery and 1 year postpartum. *Am J Obstet Gynecol.*
1156   2015;213(3):367.e1-9.
1157   48.   Bidarimath M, Edwards AK, Wessels JM, Khalaj K, Kridli RT, and Tayade C. Distinct microRNA
1158   expression in endometrial lymphocytes, endometrium, and trophoblast during spontaneous
1159   porcine fetal loss. *Journal of reproductive immunology.* 2015;107:64-79.
1160   49.   Gao Y, She R, Wang Q, Li Y, and Zhang H. Up-regulation of miR-299 suppressed the invasion and
1161   migration of HTR-8/SVneo trophoblast cells partly via targeting HDAC2 in pre-eclampsia.
1162   *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.* 2018;97:1222-8.
1163   50.   Sandrim VC, Luizon MR, Palei AC, Tanus-Santos JE, and Cavalli RC. Circulating microRNA
1164   expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels. *BJOG : an*
1165   *international journal of obstetrics and gynaecology.* 2016;123(13):2120-8.
1166   51.   Rodosthenous RS, Burris HH, Sanders AP, Just AC, Dereix AE, Svensson K, et al. Second trimester
1167   extracellular microRNAs in maternal blood and fetal growth: An exploratory study. *Epigenetics.*
1168   2017;12(9):804-10.
1169   52.   Martinez-Fierro ML, Garza-Veloz I, Gutierrez-Arteaga C, Delgado-Enciso I, Barbosa-Cisneros OY,
1170   Flores-Morales V, et al. Circulating levels of specific members of chromosome 19 microRNA

cluster are associated with preeclampsia development. *Archives of gynecology and obstetrics.*
2018;297(2):365-71.

53.   Yang S, Li H, Ge Q, Guo L, and Chen F. Deregulated microRNA species in the plasma and placenta
of patients with preeclampsia. *Molecular medicine reports.* 2015;12(1):527-34.

54.   Hromadnikova I, Kotlabova K, Ivankova K, and Krofta L. First trimester screening of circulating
C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia
and IUGR. *PLOS ONE.* 2017;12(2):e0171756.

55.   Zhang M, Muralimanoharan S, Wortman AC, and Mendelson CR. Primate-specific miR-515 family
members inhibit key genes in human trophoblast differentiation and are upregulated in
preeclampsia. *Proceedings of the National Academy of Sciences of the United States of America.*
2016;113(45):E7069-E76.

56.   Mei Z, Huang B, Mo Y, and Fan J. An exploratory study into the role of miR-204-5p in pregnancy-
induced hypertension. *Experimental and therapeutic medicine.* 2017;13(5):1711-8.

57.   Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, et al. MicroRNA expression profiles in placenta
with severe preeclampsia using a PNA-based microarray. *Placenta.* 2013;34(9):799-804.

58.   Kaufmann P, Black S, and Huppertz B. Endovascular trophoblast invasion: implications for the
pathogenesis of intrauterine growth retardation and preeclampsia. *Biol Reprod.* 2003;69(1):1-7.

59.   Barrientos G, Pussetto M, Rose M, Staff AC, Blois SM, and Toblli JE. Defective trophoblast
invasion underlies fetal growth restriction and preeclampsia-like symptoms in the stroke-prone
spontaneously hypertensive rat. *Molecular human reproduction.* 2017;23(7):509-19.

60.   Roberts JM, and Escudero C. The placenta in preeclampsia. *Pregnancy hypertension.*
2012;2(2):72-83.

61.   Fisher SJ. Why is placentation abnormal in preeclampsia? *American journal of obstetrics and*
gynecology. 2015;213(4 0):S115-S22.

62.   Crosley EJ, Elliot MG, Christians JK, and Crespi BJ. Placental invasion, preeclampsia risk and
adaptive molecular evolution at the origin of the great apes: evidence from genome-wide
analyses. *Placenta.* 2013;34(2):127-32.

63.   Lyall F, Bulmer JN, Duffie E, Cousins F, Theriault A, and Robson SC. Human Trophoblast Invasion
and Spiral Artery Transformation : The Role of PECAM-1 in Normal Pregnancy, Preeclampsia, and
Fetal Growth Restriction. *The American Journal of Pathology.* 2001;158(5):1713-21.

64.   Goldman-Wohl D, and Yagel S. Regulation of trophoblast invasion: from normal implantation to
pre-eclampsia. *Molecular and cellular endocrinology.* 2002;187(1-2):233-8.

65.   Balaraman S, Lunde ER, Sawant O, Cudd TA, Washburn SE, and Miranda RC. Maternal and
neonatal plasma microRNA biomarkers for fetal alcohol exposure in an ovine model. *Alcohol Clin*
Exp Res. 2014;38(5):1390-400.

66.   Panwar B, Omenn GS, and Guan Y. miRmine: a database of human miRNA expression profiles.
Bioinformatics. 2017;33(10):1554-60.

67.   Vicovac L, and Aplin JD. Epithelial-mesenchymal transition during trophoblast differentiation.
Acta anatomica. 1996;156(3):202-16.

68.   Knöfler M, and Pollheimer J. Human placental trophoblast invasion and differentiation: a
particular focus on Wnt signaling. *Frontiers in Genetics.* 2013;4:190.

69.   Arimoto-Ishida E, Sakata M, Sawada K, Nakayama M, Nishimoto F, Mabuchi S, et al. Up-
regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of
extravillous trophoblast cells during early implantation. *Endocrinology.* 2009;150(9):4306-15.

70.   Sun YY, Lu M, Xi XW, Qiao QQ, Chen LL, Xu XM, et al. Regulation of epithelial-mesenchymal
transition by homeobox gene DLX4 in JEG-3 trophoblast cells: a role in preeclampsia.
Reproductive sciences (Thousand Oaks, Calif). 2011;18(11):1138-45.

71.   Barrak J, Msheik H, Abou-Kheir W, and Daoud G. Assessment of different trophoblast cell lines
as in vitro models for placental development. *Placenta.* 2016;45:106.
72.   Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, et al. Epithelial-to-
mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis.
Nature medicine. 2015;21(9):998-1009.
73.   Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, and Nieto MA. Snail blocks the cell cycle
and confers resistance to cell death. *Genes & development.* 2004;18(10):1131-43.
74.   Kolahi KS, Valent AM, and Thornburg KL. Cytotrophoblast, Not Syncytiotrophoblast, Dominates
Glycolysis and Oxidative Phosphorylation in Human Term Placenta. *Scientific Reports.*
2017;7:42941.
75.   Lu X, He Y, Zhu C, Wang H, Chen S, and Lin HY. Twist1 is involved in trophoblast syncytialization
by regulating GCM1. *Placenta.* 2016;39:45-54.
76.   Omata W, Ackerman WEIV, Vandre DD, and Robinson JM. Trophoblast Cell Fusion and
Differentiation Are Mediated by Both the Protein Kinase C and A Pathways. *PLOS ONE.*
2013;8(11):e81003.
77.   Moreau R, Hamel A, Daoud G, Simoneau L, and Lafond J. Expression of calcium channels along
the differentiation of cultured trophoblast cells from human term placenta. *Biol Reprod.*
2002;67(5):1473-9.
78.   Spaans F, Melgert BN, Chiang C, Borghuis T, Klok PA, de Vos P, et al. Extracellular ATP decreases
trophoblast invasion, spiral artery remodeling and immune cells in the mesometrial triangle in
pregnant rats. *Placenta.* 2014;35(8):587-95.
79.   Karl PI, Chusid J, Tagoe C, and Fisher SE. Ca2+ flux in human placental trophoblasts. *Am J Physiol.*
1997;272(6 Pt 1):C1776-80.
80.   Roberts VH, Waters LH, and Powell T. Purinergic receptor expression and activation in first
trimester and term human placenta. *Placenta.* 2007;28(4):339-47.
81.   Halmesmaki E, Autti I, Granstrom ML, Stenman UH, and Ylikorkala O. Estradiol, estriol,
progesterone, prolactin, and human chorionic gonadotropin in pregnant women with alcohol
abuse. *J Clin Endocrinol Metab.* 1987;64(1):153-6.
82.   Edelstam G, Karlsson C, Westgren M, Lowbeer C, and Swahn ML. Human chorionic gonadatropin
(hCG) during third trimester pregnancy. *Scandinavian journal of clinical and laboratory
investigation.* 2007;67(5):519-25.
83.   Soares MJ, Chakraborty D, Rumi MAK, Konno T, and Renaud SJ. Rat Placentation: An
Experimental Model For Investigating The Hemochorial Maternal-Fetal Interface. *Placenta.*
2012;33(4):233-43.
84.   Grigsby PL. Animal Models to Study Placental Development and Function throughout Normal
and Dysfunctional Human Pregnancy. *Seminars in reproductive medicine.* 2016;34(1):11-6.
85.   Vercruysse L, Caluwaerts S, Luyten C, and Pijnenborg R. Interstitial trophoblast invasion in the
decidua and mesometrial triangle during the last third of pregnancy in the rat. *Placenta.*
2006;27(1):22-33.
86.   Silva JF, and Serakides R. Intrauterine trophoblast migration: A comparative view of humans and
rodents. *Cell Adhesion & Migration.* 2016;10(1-2):88-110.
87.   Kurtzman JT, Wilson H, and Rao CV. A Proposed Role for hCG in Clinical Obstetrics. *Semin Reprod
Med.* 2001;19(01):063-8.
88.   Furcron A-E, Romero R, Mial TN, Balancio A, Panaitescu B, Hassan SS, et al. Human Chorionic
Gonadotropin Has Anti-Inflammatory Effects at the Maternal-Fetal Interface and Prevents
Endotoxin-Induced Preterm Birth, but Causes Dystocia and Fetal Compromise in Mice. *Biology of
Reproduction.* 2016;94(6):136.

89. Henderson GI, Hoyumpa AM, Jr., McClain C, and Schenker S. The effects of chronic and acute
alcohol administration on fetal development in the rat. *Alcohol Clin Exp Res.* 1979;3(2):99-106.
90. O'Leary-Moore SK, Parnell SE, Godin EA, Dehart DB, Ament JJ, Khan AA, et al. Magnetic
resonance microscopy-based analyses of the brains of normal and ethanol-exposed fetal mice.
Birth Defects Res A Clin Mol Teratol. 2010;88(11):953-64.
91. Lo JO, Schabel MC, Roberts VH, Wang X, Lewandowski KS, Grant KA, et al. First trimester alcohol
exposure alters placental perfusion and fetal oxygen availability affecting fetal growth and
development in a non-human primate model. *Am J Obstet Gynecol.* 2017;216(3):302.e1-.e8.
92. Bake S, Tingling JD, and Miranda RC. Ethanol exposure during pregnancy persistently attenuates
cranially directed blood flow in the developing fetus: evidence from ultrasound imaging in a
murine second trimester equivalent model. *Alcohol Clin Exp Res.* 2012;36(5):748-58.
93. Gaccioli F, and Lager S. Placental Nutrient Transport and Intrauterine Growth Restriction.
Frontiers in Physiology. 2016;7:40.
94. Haggarty P, Abramovich DR, and Page K. The effect of maternal smoking and ethanol on fatty
acid transport by the human placenta. *The British journal of nutrition.* 2002;87(3):247-52.
95. Lui S, Jones RL, Robinson NJ, Greenwood SL, Aplin JD, and Tower CL. Detrimental Effects of
Ethanol and Its Metabolite Acetaldehyde, on First Trimester Human Placental Cell Turnover and
Function. *PLOS ONE.* 2014;9(2):e87328.
96. Rufer ES, Tran TD, Attridge MM, Andrzejewski ME, Flentke GR, and Smith SM. Adequacy of
Maternal Iron Status Protects against Behavioral, Neuroanatomical, and Growth Deficits in Fetal
Alcohol Spectrum Disorders. *PLoS ONE.* 2012;7(10):e47499.
97. Huebner SM, Blohowiak SE, Kling PJ, and Smith SM. Prenatal Alcohol Exposure Alters Fetal Iron
Distribution and Elevates Hepatic Hepcidin in a Rat Model of Fetal Alcohol Spectrum Disorders.
The Journal of Nutrition. 2016;146(6):1180-8.
98. Xie L, Mouillet J-F, Chu T, Parks WT, Sadovsky E, Knöfler M, et al. C19MC MicroRNAs Regulate
the Migration of Human Trophoblasts. *Endocrinology.* 2014;155(12):4975-85.
99. Salomon C, Torres MJ, Kobayashi M, Scholz-Romero K, Sobrevia L, Dobierzewska A, et al. A
Gestational Profile of Placental Exosomes in Maternal Plasma and Their Effects on Endothelial
Cell Migration. *PLOS ONE.* 2014;9(6):e98667.
100. Ouyang Y, Mouillet J-F, Coyne CB, and Sadovsky Y. Placenta-specific microRNAs in exosomes –
good things come in nano-packages. *Placenta.* 2014;35 Suppl:S69-S73.
101. Sabapatha A, Gercel-Taylor C, and Taylor DD. Specific isolation of placenta-derived exosomes
from the circulation of pregnant women and their immunoregulatory consequences. *American
journal of reproductive immunology (New York, NY : 1989).* 2006;56(5-6):345-55.
102. Nair S, and Salomon C. Extracellular vesicles and their immunomodulatory functions in
pregnancy. *Seminars in immunopathology.* 2018.
103. Delorme-Axford E, Donker RB, Mouillet J-F, Chu T, Bayer A, Ouyang Y, et al. Human placental
trophoblasts confer viral resistance to recipient cells. *Proceedings of the National Academy of
Sciences of the United States of America.* 2013;110(29):12048-53.
104. Donker RB, Mouillet JF, Chu T, Hubel CA, Stolz DB, Morelli AE, et al. The expression profile of
C19MC microRNAs in primary human trophoblast cells and exosomes. *Molecular human
reproduction.* 2012;18(8):417-24.
105. Cronqvist T, Tannetta D, Mörgelin M, Belting M, Sargent I, Familari M, et al. Syncytiotrophoblast
derived extracellular vesicles transfer functional placental miRNAs to primary human endothelial
cells. *Scientific Reports.* 2017;7(1):4558.
106. Smith SM, Garic A, Flentke GR, and Berres ME. Neural Crest Development in Fetal Alcohol
Syndrome. *Birth defects research Part C, Embryo today : reviews.* 2014;102(3):210-20.

107.   Kalcheim C. Epithelial–Mesenchymal Transitions during Neural Crest and Somite Development. *Journal of Clinical Medicine.* 2016;5(1):1.

108.   Yang J, Qiu H, Qu P, Zhang R, Zeng L, and Yan H. Prenatal Alcohol Exposure and Congenital Heart Defects: A Meta-Analysis. *PLoS ONE.* 2015;10(6):e0130681.

109.   Burd L, Deal E, Rios R, Adickes E, Wynne J, and Klug MG. Congenital heart defects and fetal alcohol spectrum disorders. *Congenital heart disease.* 2007;2(4):250-5.

110.   Serrano M, Han M, Brinez P, and Linask KK. Fetal alcohol syndrome: cardiac birth defects in mice and prevention with folate. *Am J Obstet Gynecol.* 2010;203(1):75.e7-.e15.

111.   Sarmah S, and Marrs JA. Complex cardiac defects after ethanol exposure during discrete cardiogenic events in zebrafish: Prevention with folic acid. *Developmental dynamics : an official publication of the American Association of Anatomists.* 2013;242(10):1184-201.

112.   Combs MD, and Yutzey KE. Heart Valve Development: Regulatory networks in development and disease. *Circulation research.* 2009;105(5):408-21.

113.   Lin C-J, Lin C-Y, Chen C-H, Zhou B, and Chang C-P. Partitioning the heart: mechanisms of cardiac septation and valve development. *Development (Cambridge, England).* 2012;139(18):3277-99.

114.   Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. *The New England journal of medicine.* 2013;368(18):1685-94.

115.   Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. *Invest New Drugs.* 2017;35(2):180-8.

116.   Sathyan P, Golden HB, and Miranda RC. Competing interactions between micro-RNAs determine neural progenitor survival and proliferation after ethanol exposure: evidence from an ex vivo model of the fetal cerebral cortical neuroepithelium. *J Neurosci.* 2007;27(32):8546-57.

117.   Huang W, Tian SS, Hang PZ, Sun C, Guo J, and Du ZM. Combination of microRNA-21 and microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial Infarction in Mice. *Molecular therapy Nucleic acids.* 2016;5:e296.

118.   Brady ML, Allan AM, and Caldwell KK. A Limited Access Mouse Model of Prenatal Alcohol Exposure that Produces Long-Lasting Deficits in Hippocampal-Dependent Learning and Memory. *Alcoholism, clinical and experimental research.* 2012;36(3):457-66.

119.   Kajimoto K, Allan A, and Cunningham LA. Fate Analysis of Adult Hippocampal Progenitors in a Murine Model of Fetal Alcohol Spectrum Disorder (FASD). *PLoS ONE.* 2013;8(9):e73788.

120.   Watson ED, and Cross JC. Development of structures and transport functions in the mouse placenta. *Physiology (Bethesda).* 2005;20:180-93.

121.   Gårdebjer EM, Anderson ST, Pantaleon M, Wlodek ME, and Moritz KM. Maternal alcohol intake around the time of conception causes glucose intolerance and insulin insensitivity in rat offspring, which is exacerbated by a postnatal high-fat diet. *The FASEB Journal.* 2015;29(7):2690-701.

122.   Grant KA, Leng X, Green HL, Szeliga KT, Rogers LS, and Gonzales SW. Drinking typography established by scheduled induction predicts chronic heavy drinking in a monkey model of ethanol self-administration. *Alcohol Clin Exp Res.* 2008;32(10):1824-38.

123.   Carter AM. Animal models of human placentation--a review. *Placenta.* 2007;28 Suppl A:S41-7.

124.   Orendi K, Gauster M, Moser G, Meiri H, and Huppertz B. The choriocarcinoma cell line BeWo: syncytial fusion and expression of syncytium-specific proteins. *Reproduction (Cambridge, England).* 2010;140(5):759-66.

125.   Oh SY, Hwang JR, Lee Y, Choi SJ, Kim JS, Kim JH, et al. Isolation of basal membrane proteins from BeWo cells and their expression in placentas from fetal growth-restricted pregnancies. *Placenta.* 2016;39:24-32.

126.   Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-
1361   source platform for biological-image analysis. *Nature methods.* 2012;9(7):676-82.
1362   127.   Gong J, Wu Y, Zhang X, Liao Y, Sibanda VL, Liu W, et al. Comprehensive analysis of human small
1363   RNA sequencing data provides insights into expression profiles and miRNA editing. *RNA biology.*
1364   2014;11(11):1375-85.

1365